[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4713
1. Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P, Hopkins H, Hutton B, Mcdiarmid S, Huebsch LB: A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant; 2007 Aug;13(8):956-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
  • Autologous stem cell transplant (ASCT) has been shown to be an effective treatment for follicular lymphoma (FL).
  • We explored our experience in ASCT for FL among all patients treated over a 15-year period from diagnosis through their entire treatment history including relapse post ASCT.
  • The median OS from diagnosis was 16 years for the FL-NT.
  • Unpurged ASCT is an effective tool in the treatment of relapsed, aggressive FL-NT and FL-T, is superior to retreatment with standard chemotherapy, is effective at various stages of treatment, is likely to have a beneficial influence on the natural history of this disease, and the disease is amenable to salvage therapy post-ASCT relapse.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoma, Follicular / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Ontario. Retrospective Studies. Transplantation, Autologous / methods

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640600.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander AR: Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant; 2006 Jan;37(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
  • We examined retrospectively 44 patients with refractory acute leukemia (acute myeloid leukemia (AML)/acute lymphoblastic leukemia=25/19) who underwent allogeneic transplantation at our center between 11/1990 and 04/2004.
  • All patients had graft-versus-host disease (GVHD) prophylaxis with cyclosporin and methotrexate.
  • Severe acute-GVHD and chronic-GVHD appeared in eight and 14 patients, respectively.
  • We conclude that patients with refractory leukemia can benefit from allogeneic BMT, especially with < or =20% marrow blast.
  • [MeSH-major] Blast Crisis / therapy. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Myeloablative Agonists / administration & dosage. Retrospective Studies. Transplantation, Homologous. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258531.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


3. Mori T, Aisa Y, Nakazato T, Yamazaki R, Shimizu T, Mihara A, Yamane A, Ikeda Y, Okamoto S: Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies. Transplant Proc; 2007 Jun;39(5):1615-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
  • Eighteen patients with hematologic malignancies underwent cord blood transplantation (CBT) from unrelated donors after being conditioned with myeloablative or reduced-intensity regimens, and received tacrolimus and methotrexate (15 mg/m(2) on day 1, 10 mg/m(2) on days 3 and 6) as graft-versus-host disease (GVHD) prophylaxis.
  • Of the 16 evaluable patients, five and eight had grades I and II acute GVHD, respectively, and none had grades III/IV acute GVHD.
  • The cumulative incidence of grade II acute GVHD was 44.4%.
  • Of the 18 patients, 14 were alive and disease-free between 173 and 1514 days after CBT (median 746 days).
  • The probability of disease-free survival at 2 years was 79.1%.
  • These results, although in a retrospective study, suggested that tacrolimus and short-term methotrexate effectively prevented the occurrence of severe acute GVHD after unrelated CBT, and may contribute to a high survival rate.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / adverse effects. Graft vs Host Disease / prevention & control. Hematologic Neoplasms / therapy. Methotrexate / therapeutic use. Tacrolimus / therapeutic use
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Immunosuppressive Agents / therapeutic use. Leukemia / therapy. Leukocyte Count. Lymphoma / therapy. Male. Middle Aged. Myelodysplastic Syndromes / therapy. Neutrophils. Probability. Transplantation Conditioning

  • Genetic Alliance. consumer health - Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580201.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, Burmeister T, Schwartz S, Blau O, Keilholz U, Busse A, Hoelzer D, Thiel E, Hofmann WK, Baldus CD: Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica; 2010 Jun;95(6):942-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.
  • BACKGROUND: The role of the Wilms tumor 1 gene (WT1) in acute leukemias has been underscored by mutations found in acute myeloid leukemia identifying patients with inferior survival.
  • Furthermore, aberrant expression of WT1 in acute myeloid leukemia was associated with an increased risk of relapse.
  • No larger studies have performed a combined approach including WT1 mutation and expression analyses in acute T-lymphoblastic leukemia.
  • DESIGN AND METHODS: We analyzed the WT1 mutations and the expression status in a total of 252 consecutive adult patients with newly diagnosed T-lymphoblastic leukemia, who were registered on the GMALL 06/99 and 07/03 protocols and had sufficient material available.
  • The GMALL protocols included intensive chemotherapy as well as stem cell transplantation according to a risk-based model with indication for stem cell transplantation in first complete remission for early and mature T-lymphoblastic leukemia patients; patients with thymic T-lymphoblastic leukemia were allocated to a standard risk group and treated with intensive chemotherapy.
  • In thymic T-lymphoblastic leukemia, WT1mut patients had an inferior relapse-free survival compared to WT1 wild-type patients.
  • T-lymphoblastic leukemia patients with aberrant WT1 expression (high or negative) showed a higher relapse rate and an inferior outcome compared to patients with intermediate WT1 expression.
  • In the standard risk group of thymic T-lymphoblastic leukemia, aberrant WT1 expression was predictive for an inferior relapse-free survival as compared to patients with intermediate expression.
  • CONCLUSIONS: WT1 mutations were associated with an inferior relapse-free survival in standard risk thymic T-lymphoblastic leukemia patients.
  • Moreover, altered expression associated with inferior outcome also suggests a role of WT1 in T-lymphoblastic leukemia and the potential use of molecularly-based treatment stratification to improve outcome.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, Wilms Tumor / physiology. Mutation / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate / trends. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Leukemia. 1995 Jun;9(6):1060-7 [7596170.001]
  • [Cites] Exp Hematol. 1997 Apr;25(4):312-20 [9131006.001]
  • [Cites] Leukemia. 1997 May;11(5):639-43 [9180285.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1217-25 [9242555.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2961-8 [9531607.001]
  • [Cites] EMBO J. 1999 Jul 15;18(14):3990-4003 [10406804.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1416-23 [15920493.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4414-5 [16326981.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] Haematologica. 2006 Feb;91(2):270-1 [16461320.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1507-15 [16575000.001]
  • [Cites] Oncogene. 2006 Jul 13;25(30):4217-29 [16518414.001]
  • [Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Expert Rev Mol Med. 2007;9(14):1-17 [17524167.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Leukemia. 2008 Apr;22(4):762-70 [18185524.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Blood. 2009 Jul 30;114(5):1038-45 [19494353.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3303-12 [16380455.001]
  • [Cites] EMBO J. 2001 Apr 17;20(8):1897-909 [11296223.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1914-22 [11753613.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):409-20 [11841446.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):463-70 [12841384.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Haematologica. 2004 Aug;89(8):926-33 [15339675.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1989 Apr;73(5):1247-58 [2467704.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):6198-206 [8119964.001]
  • [Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]
  • (PMID = 20435628.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2878792
  •  go-up   go-down


5. Laybourn P: The ups and downs of Tax and histones in adult T-cell leukemogenesis. Future Oncol; 2008 Jun;4(3):311-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The ups and downs of Tax and histones in adult T-cell leukemogenesis.
  • [MeSH-major] Gene Products, tax / physiology. Histones / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18518755.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Histones
  •  go-up   go-down


6. Archambault-Grenier MA, Roy J, Beauchemin N, Cohen S, Lachance S, Kiss T: Munchausen's syndrome in the allogeneic stem cell transplantation setting: a rare but potentially devastating condition. Bone Marrow Transplant; 2010 Mar;45(3):600-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Munchausen's syndrome in the allogeneic stem cell transplantation setting: a rare but potentially devastating condition.
  • [MeSH-major] Munchausen Syndrome / diagnosis. Munchausen Syndrome / psychology. Stem Cell Transplantation / psychology
  • [MeSH-minor] Female. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19668234.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


7. Asgarian Omran H, Shabani M, Shahrestani T, Sarafnejad A, Khoshnoodi J, Vossough P, Faranoush M, Sharifian RA, Jeddi-Tehrani M, Rabbani H, Shokri F: Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome. Iran J Immunol; 2007 Mar;4(1):15-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome.
  • BACKGROUND: Immunophenotypic characterization of the leukemic cells has been widely used as a tool for diagnosis, classification, stratification and prognosis of leukaemia.
  • OBJECTIVE: To investigate the immunophenotypic subtype profiles of Iranian patients with acute lymphoblastic leukemia (ALL) and its association to disease outcome.
  • Clinical manifestations and laboratory findings of the patients did not reveal association with immunophenotypic subtypes of ALL, with the exception of mediastinal mass and WBC count at the time of diagnosis which were found to be significantly higher in patients with T-ALL compared with B-ALL (p=0.001 and 0.014), respectively.
  • CONCLUSION: Our results indicate that overall the immunophenotypic profile of Iranian ALL patients is similar to previous reports and it might be used for monitoring of minimal residual disease and prognosis.
  • [MeSH-major] Immunophenotyping. Leukemia, B-Cell / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Adult. Child. Disease Progression. Humans. Iran / epidemiology. Predictive Value of Tests. Recurrence

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652839.001).
  • [ISSN] 1735-1383
  • [Journal-full-title] Iranian journal of immunology : IJI
  • [ISO-abbreviation] Iran J Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  •  go-up   go-down


8. Di Sabatino A, Miceli E, Dhaliwal W, Biancheri P, Salerno R, Cantoro L, Vanoli A, De Vincenzi M, Blanco Cdel V, MacDonald TT, Corazza GR: Distribution, proliferation, and function of Paneth cells in uncomplicated and complicated adult celiac disease. Am J Clin Pathol; 2008 Jul;130(1):34-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution, proliferation, and function of Paneth cells in uncomplicated and complicated adult celiac disease.
  • Because controversies remain concerning Paneth cell numbers and function in celiac disease (CD), we quantified Paneth cells and human alpha-defensin (HD)-5 and HD-6 in 28 patients with uncomplicated CD, 8 patients with complicated CD (3 with ulcerative jejunoileitis, 2 with refractory sprue, and 3 with enteropathy-associated T-cell lymphoma), and 14 control subjects.
  • Paneth cell numbers and proliferation did not differ in uncomplicated untreated and treated CD and control cases.
  • Paneth cell numbers and alpha-defensins are unchanged in the mucosa in uncomplicated CD.
  • [MeSH-major] Celiac Disease / pathology. Paneth Cells / pathology
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Duodenum / pathology. Female. Humans. Intestinal Mucosa / pathology. Ki-67 Antigen / analysis. Male. Middle Aged. RNA, Messenger / metabolism. alpha-Defensins / analysis

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550468.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / alpha-Defensins; 0 / human neutrophil peptide 1
  •  go-up   go-down


9. Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S, Ely S, Mazumdar M, Cesarman E, Leonard JP, Furman RR, Chen-Kiang S, Niesvizky R: Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol; 2008 Dec;143(5):654-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
  • The M-protein is the major reference measure for response in multiple myeloma (MM) and its correct interpretation is key to clinical management.
  • The emergence of oligoclonal banding is recognized as a benign finding in the postautologous stem cell transplantation setting (ASCT) for MM but its significance during non-myeloablative therapy is unknown.
  • ASIPs were not associated with new clonal plasma cells or other lymphoproliferative processes, and molecular remissions were documented.
  • Analogous to the ASCT experience, ASIPs do not signal incipient disease progression, but rather herald robust response.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. Clarithromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Dec 15;84(12):4374-82 [7994052.001]
  • [Cites] Nephrol Dial Transplant. 1997 Jun;12(6):1199-203 [9198051.001]
  • [Cites] Blood. 1998 May 1;91(9):3518-23 [9558413.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):208-15 [10458235.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1614-21 [15507523.001]
  • [Cites] Mayo Clin Proc. 2006 May;81(5):693-703 [16706268.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] Nat Rev Immunol. 2006 Oct;6(10):741-50 [16977339.001]
  • [Cites] Nat Immunol. 2007 Apr;8(4):419-29 [17322888.001]
  • [Cites] Br J Haematol. 2004 Aug;126(3):348-54 [15257706.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1927-9 [12738666.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1777-82 [12685831.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2273-81 [10829048.001]
  • [Cites] Bone Marrow Transplant. 2000 Apr;25(7):723-8 [10745257.001]
  • [Cites] Clin Chem. 1991 Aug;37(8):1334-7 [1907894.001]
  • [Cites] Blood. 1989 Dec;74(8):2764-8 [2819246.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1101-9 [17989313.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3153-7 [8499649.001]
  • (PMID = 18950461.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA109260; United States / NCI NIH HHS / CA / K23 CA109260-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins; 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide; H1250JIK0A / Clarithromycin
  • [Other-IDs] NLM/ NIHMS453628; NLM/ PMC3626496
  •  go-up   go-down


10. Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, Pagano L, Bernengo MG, Zaja F, Rupoli S, Pileri S, Baccarani M, Zinzani PL: Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer; 2005 Dec 1;104(11):2437-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
  • BACKGROUND: Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T-cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL.
  • METHODS: Between June 2002 and February 2004, 32 untreated patients with mycosis fungoides (MF) (n = 26 patients); peripheral T-cell lymphoma, unspecified (PTCLU) with exclusive skin involvement (n = 5 patients); and Sezary syndrome (SS) (n = 1 patient) were enrolled in a 7-institution, Phase II trial and treated with gemcitabine.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / toxicity. Deoxycytidine / analogs & derivatives. Lymphoma, T-Cell, Cutaneous / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216001.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


11. Pais-Correia AM, Sachse M, Guadagnini S, Robbiati V, Lasserre R, Gessain A, Gout O, Alcover A, Thoulouze MI: Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med; 2010 Jan;16(1):83-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses.
  • Human T cell leukemia virus type 1 (HTLV-1) is a lymphotropic retrovirus whose cell-to-cell transmission requires cell contacts.
  • HTLV-1-infected T lymphocytes form 'virological synapses', but the mechanism of HTLV-1 transmission remains poorly understood.
  • We show here that HTLV-1-infected T lymphocytes transiently store viral particles as carbohydrate-rich extracellular assemblies that are held together and attached to the cell surface by virally-induced extracellular matrix components, including collagen and agrin, and cellular linker proteins, such as tetherin and galectin-3.
  • Extracellular viral assemblies rapidly adhere to other cells upon cell contact, allowing virus spread and infection of target cells.
  • Their removal strongly reduces the ability of HTLV-1-producing cells to infect target cells.
  • Our findings unveil a novel virus transmission mechanism based on the generation of extracellular viral particle assemblies whose structure, composition and function resemble those of bacterial biofilms.
  • HTLV-1 biofilm-like structures represent a major route for virus transmission from cell to cell.
  • [MeSH-major] CD4-Positive T-Lymphocytes / virology. Extracellular Matrix / virology. HTLV-I Infections / transmission. Human T-lymphotropic virus 1 / physiology
  • [MeSH-minor] Biofilms. Concanavalin A. Gene Products, env / metabolism. Humans. Microscopy, Electron, Transmission. Virus Assembly / physiology. Virus Attachment. Virus Internalization

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Med. 2010 Jan;16(1):25-7 [20057417.001]
  • (PMID = 20023636.001).
  • [ISSN] 1546-170X
  • [Journal-full-title] Nature medicine
  • [ISO-abbreviation] Nat. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, env; 11028-71-0 / Concanavalin A
  •  go-up   go-down


12. Yu Q, Minoda Y, Yoshida R, Yoshida H, Iha H, Kobayashi T, Yoshimura A, Takaesu G: HTLV-1 Tax-mediated TAK1 activation involves TAB2 adapter protein. Biochem Biophys Res Commun; 2008 Jan 4;365(1):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-1 Tax-mediated TAK1 activation involves TAB2 adapter protein.
  • Human T cell leukemia virus type 1 (HTLV-1) Tax is an oncoprotein that plays a crucial role in the proliferation and transformation of HTLV-1-infected T lymphocytes.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Gene Products, tax / metabolism. Human T-lymphotropic virus 1 / metabolism. MAP Kinase Kinase Kinases / metabolism
  • [MeSH-minor] Binding Sites. Cell Line. Humans. NF-kappa B / metabolism. Ubiquitin-Protein Ligases / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986383.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Gene Products, tax; 0 / NF-kappa B; 0 / TAB2 protein, human; 0 / tax protein, Human T-lymphotrophic virus 1; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / MAP kinase kinase kinase 7; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


13. Yano H, Ishida T, Inagaki A, Ishii T, Kusumoto S, Komatsu H, Iida S, Utsunomiya A, Ueda R: Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer; 2007 May 1;120(9):2052-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory T-cell function of adult T-cell leukemia/lymphoma cells.
  • Adult T-cell leukemia/lymphoma (ATLL) patients are highly immunocompromised, but the underlying mechanism responsible for this state remains obscure.
  • Recent studies demonstrated that FOXP3, which is a master control gene of naturally occurring regulatory T (Treg) cells, is expressed in the tumor cells from a subset of patients with ATLL.
  • Since most ATLL cells express both CD4 and CD25, these tumors might originate from CD4(+)CD25(+)FOXP3(+) Treg cells, based on their phenotypic characteristics.
  • However, whether ATLL cells actually function as Treg cells has not yet been clearly demonstrated.
  • Here, we show that ATLL cells from a subset of patients are not only hypo-responsive to T-cell receptor-mediated activation, but also suppress the proliferation of autologous CD4(+) non-ATLL cells.
  • Furthermore, ATLL cells from this subset of patients secrete only small amounts of IFN-gamma, and suppress IFN-gamma production by autologous CD4(+) non-ATLL cells.
  • These are the first data showing that ATLL cells from a subset of patients function as Treg cells in an autologous setting.
  • The present study provides novel insights into understanding the immunopathogenesis of ATLL, i.e., how HTLV-1-infected cells can survive in the face of host immune responses.
  • It also adds to our understanding of ATLL patients' severely immunocompromised state.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / immunology. T-Lymphocytes, Regulatory / physiology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17278106.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00355472
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCR4 protein, human; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / RNA, Messenger; 0 / Receptors, CCR4; 0 / Receptors, Chemokine; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


14. Grabher C, von Boehmer H, Look AT: Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer; 2006 May;6(5):347-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia.
  • The chromosomal translocation t(7;9) in human T-cell acute lymphoblastic leukaemia (T-ALL) results in deregulated expression of a truncated, activated form of Notch 1 (TAN1) under the control of the T-cell receptor-beta (TCRB) locus.
  • Although TAN1 efficiently induces T-ALL in mouse models, t(7;9) is present in less than 1% of human T-ALL cases.
  • The recent discovery of novel activating mutations in NOTCH1 in more than 50% of human T-ALL samples has made it clear that Notch 1 is far more important in human T-ALL pathogenesis than previously suspected.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Leukemia-Lymphoma, Adult T-Cell / metabolism. Receptor, Notch1 / metabolism

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612405.001).
  • [ISSN] 1474-175X
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  • [Number-of-references] 175
  •  go-up   go-down


15. Pennanen H, Kuittinen O, Soini Y, Turpeenniemi-Hujanen T: Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma. Eur J Haematol; 2008 Oct;81(4):289-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
  • OBJECTIVES: p53 mutations and high protein expression are associated with adverse prognosis in several lymphoma subtypes.
  • Matrix metalloproteinase-9 (MMP-9) has also been found to correlate with poor survival in all lymphomas studied.
  • The data concerning the clinical role of protein expression of p53 or gelatinases and their inhibitors in follicular lymphoma are rare.
  • The purpose of this study was to evaluate the prognostic and clinical implications of the immunoreactive proteins p53, MMP-2, MMP-9, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and TIMP-2 in follicular lymphoma.
  • METHODS: The material consisted of 67 patients with primarily non-transformed follicular lymphoma.
  • CONCLUSIONS: In this study, p53 over-expression predicted both transformation to diffuse large B-cell lymphoma and poorer overall and cause-specific survival of patients with follicular lymphoma.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Lymphoma, Follicular / metabolism. Matrix Metalloproteinase 9 / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Immunochemistry. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Matrix Metalloproteinase 2 / biosynthesis. Middle Aged. Predictive Value of Tests. Retrospective Studies. Survival Rate. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-2 / biosynthesis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616513.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tumor Suppressor Protein p53; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / MMP2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


16. Luther N, Greenfield JP, Chadburn A, Schwartz TH: Intracranial nasal natural killer/T-cell lymphoma: immunopathologically-confirmed case and review of literature. J Neurooncol; 2005 Nov;75(2):185-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial nasal natural killer/T-cell lymphoma: immunopathologically-confirmed case and review of literature.
  • Advances in immunophenotypic profiling now permit characterization of natural killer/T-cell (NK/T-cell) lymphoma as distinct from other extranodal T- and B-cell Non-Hodgkin's lymphomas.
  • NK/T-cell lymphoma presents most commonly in the nasal cavity.
  • Disease progression to the central nervous system (CNS) is a rare phenomenon.
  • We present here, to our knowledge, the first immunophenotypically-confirmed case of direct extension of nasal NK/T-cell lymphoma to the brain.
  • In addition, we review the literature with respect to NK/T-cell lymphoma metastasis to the CNS.
  • The overall prevalence of NK/T-cell lymphoma CNS metastasis is less than 3%.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / pathology. Nose Neoplasms / immunology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Antigens, CD3 / immunology. Antigens, CD4 / immunology. Antigens, CD56 / immunology. Craniotomy. Fatal Outcome. Follow-Up Studies. Humans. Immunophenotyping. Magnetic Resonance Imaging. Male. Pseudomonas aeruginosa / drug effects. Pseudomonas aeruginosa / isolation & purification. Staphylococcus aureus / drug effects. Staphylococcus aureus / isolation & purification. Time Factors

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):143-8 [6381328.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1356-69 [10555004.001]
  • [Cites] Am J Hematol. 1999 Feb;60(2):161-3 [9929112.001]
  • [Cites] Acta Oncol. 1997;36(3):307-11 [9208902.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):797-802 [2004957.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Leuk Lymphoma. 2000 Sep;39(1-2):139-44 [10975392.001]
  • [Cites] Clin Lab Haematol. 2000 Aug;22(4):215-20 [11012633.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Leuk Lymphoma. 2001 Nov-Dec;42(6):1297-303 [11911411.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • [Cites] Acta Oncol. 2003;42(7):779-83 [14690165.001]
  • [Cites] Am J Ophthalmol. 2002 Sep;134(3):406-10 [12208253.001]
  • [Cites] Curr Opin Oncol. 2003 Sep;15(5):353-62 [12960516.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1228-33 [11728681.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:259-81 [11722988.001]
  • [Cites] Histopathology. 1995 Aug;27(2):139-48 [8835262.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):70-7 [9440725.001]
  • [Cites] Med Oncol. 2003;20(1):13-7 [12665679.001]
  • (PMID = 16283442.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD56
  • [Number-of-references] 24
  •  go-up   go-down


17. Mebazaa A, Dupuy A, Rybojad M, Mouly F, Moulonguet I, Vignon-Pennamen MD, Rivet J, Janin A, Lebbé C, Dubertret L, Morel P, Bachelez H, Brice P: ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients. Hematol J; 2005;5(7):553-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients.
  • Systemic multiagent hemotherapy has been used to treat aggressive forms of primary cutaneous T-cell lymphomas (CTCL) with controversial results.
  • Two patients achieved complete remissions lasting 30+ and 6+ months, seven had partial remissions of short duration, one had stable disease and one experienced disease progression.

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692599.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


18. Lim Z, Gupta S, Salisbury JR, Elias D, Venkatram NK, Mufti GJ, Pagliuca A: T-cell lymphoblastic lymphoma presenting as an intra-muscular mass. Br J Haematol; 2006 Mar;132(5):537
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic lymphoma presenting as an intra-muscular mass.
  • [MeSH-major] Fibula / pathology. Lymphoma, T-Cell, Peripheral / diagnosis. Magnetic Resonance Imaging. Muscle, Skeletal / pathology. Tibia / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Leukemic Infiltration. Male. Positron-Emission Tomography. Testis / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445824.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Suzuki S, Uozumi K, Utsunomiya A, Ishitsuka K, Masamoto I, Owatari S, Makino T, White Y, Arima N: Aggressive NK cell leukaemia after splenectomy: association with CD95-resistant memory T-cell proliferation and recalcitrant clinical course of haemophagocytic syndrome. Eur J Haematol; 2008 Sep;81(3):236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive NK cell leukaemia after splenectomy: association with CD95-resistant memory T-cell proliferation and recalcitrant clinical course of haemophagocytic syndrome.
  • We describe a 44-yr-old Japanese woman with persistent polyclonal T-cell proliferation and recalcitrant clinical course of haemophagocytic syndrome (HPS).
  • T cells bearing alphabeta T-cell receptors (TCR) expressed increased amounts of CD95 and of CD45RO, which are phenotypically memory T cells.
  • Aggressive natural killer cell leukaemia (ANKL) without an association with Epstein-Barr virus was detected 1 month after therapeutic splenectomy that followed 3 yr of immunosuppressive therapy against HPS.
  • The immunophenotype of these leukaemia cells was CD56, CD16(dim), CD7, CD45RA and they expressed some CD2, CD8 and HLA-DR.
  • Latent NK-cell malignancy seemed to cause the CD95-resistant memory T-cell proliferation and splenectomy resulted in overt ANKL progression.
  • There should be careful consideration of the risks versus benefits of splenectomy in HPS, in light of the possibility of fatal leukaemia/lymphoma progression.
  • [MeSH-major] Antigens, CD95 / physiology. Killer Cells, Natural / immunology. Leukemia / immunology. Leukemia / therapy. Lymphohistiocytosis, Hemophagocytic / immunology. Lymphohistiocytosis, Hemophagocytic / therapy. Splenectomy / adverse effects
  • [MeSH-minor] Adult. Cell Proliferation. Chromosome Aberrations. Disease Progression. Fatal Outcome. Female. Flow Cytometry. Follow-Up Studies. Humans. Immunophenotyping. Immunosuppressive Agents / therapeutic use. Karyotyping. Risk Factors

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510705.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Immunosuppressive Agents
  •  go-up   go-down


20. Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J, Hägglund H: Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol; 2008;25(4):374-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.
  • Late-onset neutropenia, i.e. an absolute neutrophil count of <1.5 x 10(9)/l, may follow 4 weeks or more after therapy with rituximab for lymphoma.
  • In a retrospective study of 113 consecutive lymphoma patients treated with rituximab, with or without chemotherapy, we found eight patients (7%) with late-onset neutropenia (LON).
  • Four of the eight patients underwent stem cell transplantation.
  • In four subsequently identified patients with severe LON, a maturation arrest at the (pro)myelocyte stage was observed in the bone marrow, similar to that found in severe congenital neutropenia or Kostmann disease.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cell Differentiation / drug effects. DNA Mutational Analysis. Female. Humans. Lymphoma / drug therapy. Male. Middle Aged. Proteins / genetics. Rituximab. Time

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Hematol. 2002 Apr;39(2):113-20 [11957194.001]
  • [Cites] Eur J Haematol Suppl. 2007 Jan;(67):5-14 [17206982.001]
  • [Cites] Eur J Haematol Suppl. 1996;60:93-7 [8987249.001]
  • [Cites] Haematologica. 2007 Feb;92(2):e20-3 [17405749.001]
  • [Cites] Int J Hematol. 2006 Oct;84(3):242-7 [17050199.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(6):628-32 [11128813.001]
  • [Cites] Acta Paediatr. 2007 Jun;96(6):813-9 [17537008.001]
  • [Cites] Ann Pharmacother. 2005 Dec;39(12):2091-5 [16249269.001]
  • [Cites] Autoimmun Rev. 2006 Jan;5(1):18-24 [16338207.001]
  • [Cites] Curr Drug Metab. 2006 Apr;7(3):219-29 [16611018.001]
  • [Cites] Blood. 2005 Aug 1;106(3):795-802 [15718416.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):913-8 [12786803.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):1232-8 [16002727.001]
  • [Cites] Haematologica. 2004 Mar;89(3):361-3 [15020279.001]
  • [Cites] Acta Paediatr. 2006 Dec;95(12):1526-32 [17129957.001]
  • [Cites] Leuk Lymphoma. 2006 Jun;47(6):1013-7 [16840190.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):597-600 [12007508.001]
  • [Cites] Bull Cancer. 2007 Feb;94(2):198-202 [17337389.001]
  • [Cites] Cancer Treat Rev. 2005 Oct;31(6):456-73 [16054760.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):635-8 [8757135.001]
  • [Cites] Semin Hematol. 2006 Jul;43(3):189-95 [16822461.001]
  • [Cites] Blood. 2004 May 1;103(9):3355-61 [14764541.001]
  • [Cites] Bone Marrow Transplant. 2004 May;33(9):921-3 [15034544.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):86-92 [17187068.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):275-8 [15813856.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):364-9 [17079695.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2691-4; discussion 2691-4 [12826650.001]
  • (PMID = 18278570.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / HAX1 protein, human; 0 / Proteins; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


21. Ngeow JY, Quek RH, Ng DC, Hee SW, Tao M, Lim LC, Tan YH, Lim ST: High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol; 2009 Sep;20(9):1543-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
  • BACKGROUND: Data assessing the role of positron emission tomography (PET)/computed tomography (CT) imaging in lymphoma staging is still being accumulated and current staging is based primarily on CT.
  • This study aims to compare the value of PET/CT over conventional CT and bone marrow biopsy (BMB) in the initial evaluation of patients with lymphoma.
  • RESULTS: Among the 122 patients, 101 had non-Hodgkin's lymphoma (NHL) and 21 had Hodgkin's lymphoma (HL).
  • Compared with conventional CT, PET/CT upstaged 21 (17%) cases [B-cell non-Hodgkin's lymphoma (B-NHL), 12; T-cell non-Hodgkin's lymphoma (T-NHL), 3; HL, 6].
  • A maximum FDG uptake of >10 standardized uptake value (SUV) seems to significantly correlate with an aggressive B-cell lineage (odds ratio 2.47, 95% confidence interval 2.23-2.70).
  • In HL, our data show that PET scan and marrow results agreed in 19 of the cases (90%), being concordantly negative in 18 cases and concordantly positive in one, giving a negative predictive value (NPV) of 100%, sensitivity of 100% and specificity of 90%.
  • In patients with aggressive B-NHL, BMB and PET/CT agreed in 58 patients (92%) and disagreed in five (8%), while the corresponding rates in indolent B-cell lymphoma were 14 (67%) and seven patients (33%), respectively.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474116.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


22. Miura H, Maeda M, Yamamoto N, Yamaoka S: Distinct IkappaB kinase regulation in adult T cell leukemia and HTLV-I-transformed cells. Exp Cell Res; 2005 Aug 1;308(1):29-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct IkappaB kinase regulation in adult T cell leukemia and HTLV-I-transformed cells.
  • We have recently shown constitutive IkappaB kinase (IKK) activation and aberrant p52 expression in adult T cell leukemia (ATL) cells that do not express human T cell leukemia virus type I (HTLV-I) Tax, but the mechanism of IKK activation in these cells has remained unknown.
  • Here, we demonstrate distinct regulation of IKK activity in ATL and HTLV-I-transformed T cells in response to protein synthesis inhibition or arsenite treatment.
  • Protein synthesis inhibition for 4 h by cycloheximide (CHX) barely affects IKK activity in Tax-positive HTLV-I-transformed cells, while it diminishes IKK activity in Tax-negative ATL cells.
  • Treatment of ATL cells with a proteasome inhibitor MG132 prior to protein synthesis inhibition reverses the inhibitory effect of CHX, and MG132 alone greatly enhances IKK activity.
  • In addition, treatment of HTLV-I-transformed cells with arsenite for 1 h results in down-regulation of IKK activity without affecting Tax expression, while 8 h of arsenite treatment does not impair IKK activity in ATL cells.
  • These results indicate that a labile protein sensitive to proteasome-dependent degradation governs IKK activation in ATL cells, and suggest a molecular mechanism of IKK activation in ATL cells distinct from that in HTLV-I-transformed T cells.
  • [MeSH-major] Cell Transformation, Viral / physiology. Leukemia-Lymphoma, Adult T-Cell / metabolism. Protein-Serine-Threonine Kinases / metabolism
  • [MeSH-minor] Arsenites / pharmacology. Cell Line, Transformed. Cell Line, Tumor. Cycloheximide / antagonists & inhibitors. Cycloheximide / pharmacology. Enzyme Inhibitors / pharmacology. Human T-lymphotropic virus 1 / physiology. Humans. I-kappa B Kinase. Leupeptins / pharmacology. Proteasome Endopeptidase Complex / metabolism. Protein Synthesis Inhibitors / pharmacology. T-Lymphocytes / drug effects. T-Lymphocytes / metabolism

  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878527.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenites; 0 / Enzyme Inhibitors; 0 / Leupeptins; 0 / Protein Synthesis Inhibitors; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 98600C0908 / Cycloheximide; EC 2.7.1.- / IKBKE protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.10 / CHUK protein, human; EC 2.7.11.10 / I-kappa B Kinase; EC 2.7.11.10 / IKBKB protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex; N5509X556J / arsenite
  •  go-up   go-down


23. Khosravi Shahi P, Díaz Muñoz de la Espada VM: [Extranodal T/NK-cell lymphoma, nasal type: a case report and review of the literature]. An Med Interna; 2005 Dec;22(12):597-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extranodal T/NK-cell lymphoma, nasal type: a case report and review of the literature].
  • [Transliterated title] Linfoma T/NK extraganglionar tipo nasal: caso clínico y revisión de la literatura.
  • Extranodal T/NK-cell lymphoma, nasal type: a case report and review of the literature.
  • Extranodal NK/T-cell lymphoma, nasal type, is an extranodal lymphoma, usually with an NK-cell phenotype and EBV positive, with a broad morphologic spectrum, frequent necrosis and angioinvasion, and most commonly presenting in the midfacial region, but also in other extranodal sites.
  • The diagnosis of the case was Extranodal T/NK-cell lymphoma, nasal type.
  • There was not disseminated disease in the extent studies.
  • With the diagnosis of localized extranodal T/NK-cell lymphoma and reactive thrombocytosis, the patient was treated with chemotherapy and sequential radiotherapy, followed by bone marrow transplantation.
  • [MeSH-major] Killer Cells, Natural. Lymphoma, T-Cell / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Immunophenotyping. Male

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454602.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


24. Wain EM, Antony F, Appleton MA, Whittaker SJ, Robson A: Genital herpes masquerading as a cutaneous T-cell lymphoma: a report of two cases. J Cutan Pathol; 2008 Aug;35(8):770-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genital herpes masquerading as a cutaneous T-cell lymphoma: a report of two cases.
  • Genital herpes simplex virus (HSV) infection is usually a straightforward clinical diagnosis, rarely requiring histological confirmation.
  • We report two cases of immunosuppressed patients in which the clinical and pathological features were initially suspicious for cutaneous lymphoma with a T-cell clone detected in one case.
  • A diagnosis of HSV infection was eventually made on the basis of histological features and confirmed with immunohistochemistry.
  • [MeSH-major] Herpes Genitalis / pathology. Immunocompromised Host. Lymphoma, T-Cell, Cutaneous / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Male

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Genital Herpes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422691.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


25. Karaosmanoglu D, Karcaaltincaba M, Oguz B, Akata D, Ozmen M, Akhan O: CT findings of lymphoma with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis. Eur J Radiol; 2009 Aug;71(2):313-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT findings of lymphoma with peritoneal, omental and mesenteric involvement: peritoneal lymphomatosis.
  • PURPOSE: We aimed to describe computed tomography (CT) findings in patients with peritoneal, omental and mesenteric lymphoma involvement.
  • MATERIALS AND METHODS: We searched our archive retrospectively to find out patients with peritoneal, omental and mesenteric lymphoma involvement.
  • We found 16 patients with non-Hodgkin lymphoma meeting these criteria.
  • CT studies of these patients were reevaluated for the presence of peritoneal involvement, ascites, omental mass, organomegaly, retroperitoneal lymphadenopathy, bowel wall thickening and other associated findings.
  • RESULTS: There were 14 males and 2 females with peritoneal and/or mesenteric and omental lymphoma involvement.
  • Subgroups of non-Hodgkin lymphoma were diffuse large B-cell lymphoma (n=11), small cell lymphocytic lymphoma (n=2), small cleaved cell lymphoma (n=1), T-cell lymphoma (n=1) and Burkitt's lymphoma (n=1).
  • CONCLUSION: Peritoneal involvement can be seen in many subtypes of lymphoma and most frequently in diffuse large B-cell lymphoma.
  • Peritoneal lymphomatosis can mimic peritoneal carcinomatosis and should be included in the differential diagnosis list in patients with ascites, hepatosplenic lesions and unidentified cause of peritoneal thickening on CT in a male patient.
  • [MeSH-major] Lymphoma / radiography. Mesentery / radiography. Omentum / radiography. Peritoneal Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18513906.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


26. Parker NP, Pearlman AN, Conley DB, Kern RC, Chandra RK: The dilemma of midline destructive lesions: a case series and diagnostic review. Am J Otolaryngol; 2010 Mar-Apr;31(2):104-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Midline destructive lesions (MDLs) of the nose are a diagnostic dilemma due to an extensive differential diagnosis and vague presenting signs and symptoms.
  • Laboratory tests included complete blood count, basic metabolic panel, erythrocyte sedimentation rate, angiotensin-converting enzyme, antineutrophil antibodies, rheumatoid factor, anti-Ro and anti-La antibodies, Epstein-Barr virus antibodies, coccidiomycosis serology, HIV antibodies, fluorescent treponemal antibody absorption, classic antineutrophil cytoplasmic antibodies, perinuclear antineutrophil cytoplasmic antibody, proteinase 3, and myeloperoxidase.
  • Two patients were diagnosed with natural killer/T-cell lymphoma, 2 were diagnosed with Wegener's granulomatosis, and 4 remained idiopathic, despite the extensive workup.
  • CONCLUSIONS: The diagnosis of MDLs remains difficult but is aided by a systematic approach and familiarity with multiple diagnostic techniques.
  • It is imperative to take multiple tissue specimens from various sites, send them fresh, and communicate suspicion of lymphoma.
  • [MeSH-major] Granuloma, Lethal Midline / diagnosis
  • [MeSH-minor] Adult. Algorithms. Diagnosis, Differential. Female. Granulomatosis with Polyangiitis / diagnosis. Humans. Lymphoma, T-Cell / diagnosis. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20015726.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


27. Ohsugi T, Kumasaka T, Okada S, Ishida T, Yamaguchi K, Horie R, Watanabe T, Umezawa K: Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines. Cancer Lett; 2007 Nov 18;257(2):206-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
  • Adult T-cell leukemia (ATL) is an aggressive neoplasm caused by human T-cell leukemia virus type I (HTLV-I), which induces nuclear factor-kappaB (NF-kappaB), a molecule central to the ensuing neoplasia.
  • The NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) has been shown to inhibit NF-kappaB activation in Tax-expressing HTLV-I-infected cells.
  • In this study, we used NOD/SCID beta2-microglobulin(null) mice to show that intraperitoneal inoculation with Tax-deficient ATL cell lines caused rapid death, whereas DHMEQ-treated mice survived.
  • Furthermore, DHMEQ treatment after subcutaneous inoculation inhibited the growth of transplanted ATL cells.
  • These results demonstrate that DHMEQ has therapeutic efficacy on ATL cells, regardless of Tax expression.
  • [MeSH-major] Benzamides / pharmacology. Cyclohexanones / pharmacology. Gene Products, tax / deficiency. Leukemia, T-Cell / prevention & control. Xenograft Model Antitumor Assays / methods
  • [MeSH-minor] Adult. Animals. Apoptosis / drug effects. Cell Line, Tumor. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / metabolism. Humans. Mice. Mice, Inbred NOD. Mice, Knockout. Mice, SCID. NF-kappa B / antagonists & inhibitors. NF-kappa B / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Tumor Burden. beta 2-Microglobulin / genetics. beta 2-Microglobulin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17764832.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Benzamides; 0 / Cyclohexanones; 0 / Gene Products, tax; 0 / NF-kappa B; 0 / RNA, Messenger; 0 / beta 2-Microglobulin; 0 / dehydroxymethylepoxyquinomicin
  •  go-up   go-down


28. Tanosaki R, Uike N, Utsunomiya A, Saburi Y, Masuda M, Tomonaga M, Eto T, Hidaka M, Harada M, Choi I, Yamanaka T, Kannagi M, Matsuoka M, Okamura J: Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant; 2008 Jun;14(6):702-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for adult T cell leukemia/lymphoma (ATLL), but shows high mortality.
  • We evaluated the feasibility of reduced-intensity transplantation using fludarabine and busulfan, with particular focus on the clinical impact of antithymocyte globulin (ATG) in the conditioning regimen.
  • Fourteen elderly patients with aggressive ATLL were enrolled in the current study without ATG, and were compared to those in 15 patients who were treated similarly, but with ATG, in our previous study.
  • Analysis of combined data from both our current and previous studies disclosed that grade I-II acute GVHD was the only factor that favorably affected OS and PFS.
  • These data suggested the presence of a graft-versus-ATLL effect and the feasibility of a transplant procedure without ATG in elderly ATLL patients, but could not demonstrate the clinical benefit of incorporating ATG.
  • [MeSH-major] Antilymphocyte Serum / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunosuppressive Agents / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / surgery. Transplantation Conditioning / methods
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Human T-lymphotropic virus 1 / isolation & purification. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Proviruses / isolation & purification. Survival Analysis. T-Lymphocytes. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489996.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents
  •  go-up   go-down


29. Li SL, Zhang XL, Han HX, Chen B: [Imaging features of primary bone lymphoma and its histopathology]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Feb;27(2):201-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Imaging features of primary bone lymphoma and its histopathology].
  • OBJECTIVE: To study the imaging features of primary bone of the lymphoma PLB on X-ray, CT and magnetic resonance imaging (MRI).
  • Histological examination identified B-cell lymphoma in 5 cases and T-cell lymphoma in 4 cases.
  • [MeSH-major] Bone Neoplasms / radiography. Lymphoma / radiography. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355937.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, Mandelli F, Mecucci C, Martelli MF: Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica; 2007 Apr;92(4):519-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
  • The gene NPM1 that encodes for nucleophosmin (NPM1) is translocated or mutated in various lymphomas and leukemias, forming fusion proteins (NPM-ALK, NPM-RARalpha, NPM-MLF1) or NPM mutant products.
  • Here, we review the structure and functions of NPM, as well as the biological, clinical and pathological features of human hematologic malignancies with NPM1 gene alterations.
  • NPM-ALK indentifies a new category of T/Null lymphomas with distinctive molecular and clinico-pathological features, that is going to be included as a novel disease entity (ALK+ anaplastic large cell lymphoma) in the new WHO classification of lymphoid neoplasms.
  • NPM1 mutations occur specifically in about 30% of adult de novo AML and cause aberrant cytoplasmic expression of NPM (hence the term NPMc+ AML).
  • NPMc+ AML associates with normal karyotpe, and shows wide morphological spectrum, multilineage involvement, a unique gene expression signature, a high frequency of FLT3-internal tandem duplications, and distinctive clinical and prognostic features.
  • The availability of specific antibodies and molecular techniques for the detection of NPM1 gene alterations has an enormous impact in the biological study diagnosis, prognostic stratification, and monitoring of minimal residual disease of various lymphomas and leukemias.
  • [MeSH-major] Leukemia, Myeloid / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. Nuclear Proteins / physiology
  • [MeSH-minor] Acute Disease. Adult. Age of Onset. Alternative Splicing. Amino Acid Motifs. Biological Transport. Cell Nucleolus / metabolism. Cell Nucleus / metabolism. Child. Chromosomes, Human, Pair 5 / genetics. Cytoplasm / metabolism. Humans. Karyotyping. Mutation. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / physiology. Prognosis. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / physiology. Ribosomes / metabolism. Structure-Activity Relationship. Translocation, Genetic. Treatment Outcome

  • Genetics Home Reference. consumer health - NPM1 gene.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488663.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / NPM-MLF1 protein, human; 0 / NPM-RARalpha protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 117896-08-9 / nucleophosmin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 166
  •  go-up   go-down


31. Buie LW, Epstein SS, Lindley CM: Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther; 2007 Sep;29(9):1887-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Nelarabine was approved by the US Food and Drug Administration (FDA) in October 2005 for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to or has relapsed after treatment with at least 2 chemotherapy regimens.
  • Also reviewed are nelarabine's clinical efficacy in T-ALL, T-LBL, and other hematologic malignancies; its toxicity profile, dosage, and administration; and areas of ongoing and future research.
  • Nelarabine has activity in T-cell malignancies, as evaluated in 2 Phase I and 5 Phase II studies.
  • Among patients with central nervous system-positive T-ALL or T-cell non-Hodgkins lymphoma (T-NHL) (n = 21), 33% had an objective response (5 CR and 2 PR); among patients with T-ALL or T-NHL with extramedullary relapse (n = 22), 14% had a PR.
  • CALGB 19801 included 39 adult patients with T-cell malignancies, of whom 7 (18%) had a CR and an additional 2 (5%) had a CR without full hematologic recovery.
  • Objective response rates in Phase II clinical trials of nelarabine have ranged from 11% to 60%.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Arabinonucleosides / therapeutic use. Hematologic Neoplasms / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Purine Nucleosides / therapeutic use

  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035189.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Arabinonucleosides; 0 / Purine Nucleosides; 60158CV180 / nelarabine
  • [Number-of-references] 29
  •  go-up   go-down


32. Jian D, Wu S, Chen D, Ying M, Yang B, You Z, Liu L, Ding Z: [Nasal NK/T cell lymphoma: a report of 11 cases]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Jul;19(14):638-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nasal NK/T cell lymphoma: a report of 11 cases].
  • OBJECTIVE: To investigate the clinical diagnosis consideration of nasal NK/T cell lymphoma.
  • METHOD: Reviewing the clinical data of 11 patients with nasal NK/T cell lymphoma between 1992 to 2003.
  • CONCLUSION: Nasal NK/T cell lymphoma is easily misdiagnosed.
  • The right diagnosis can be built with clinical, pathological and imaging examination.
  • [MeSH-major] Diagnostic Errors. Lymphoma, Extranodal NK-T-Cell. Nose Neoplasms
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16248460.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Zheng YY, Chen G, Zhou XG, Zhang SH, Zhang YN: [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To study the morphologic and immunophenotypic features of angioimmunoblastic T-cell lymphoma (AITL), as well as the origin of the proliferative follicular dendritic cells (FDCs) in AITL.
  • Cases of peripheral T-cell lymphoma, unspecified, extranodal NK/T-cell lymphoma, nasal-type, enteropathy-type T-cell lymphoma, anaplastic large cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma and reactive lymphoid proliferation were selected as controls.
  • RESULTS: Amongst the 29 cases of AITL studied, 75.9% (22/29) showed aberrant expression of CD10, while all except one of the controlled cases were negative, 82.8% (24/29) of the AITL cases expressed CXCL13, while all cases of peripheral T-cell lymphoma, unspecified were negative.
  • As for bcl-6 staining, although the highest percentage of bcl-6-positive cells was observed in AITL, the expression pattern was not useful in differentiating AITL from peripheral T-cell lymphoma, unspecified and lymphoid reaction.
  • Two of the cases, which contained obvious germinal centers, had the follicular dendritic cell meshwork extending beyond the lymphoid follicles.
  • [MeSH-major] Chemokine CXCL13 / metabolism. Dendritic Cells, Follicular / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunophenotyping. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-6 / metabolism. Receptors, Complement 3d / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575853.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


34. Munir S, Le Nouen C, Luongo C, Buchholz UJ, Collins PL, Bukreyev A: Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J Virol; 2008 Sep;82(17):8780-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells.
  • Human respiratory syncytial virus (RSV) is the most important agent of serious pediatric respiratory tract disease worldwide.
  • One of the main characteristics of RSV is that it readily reinfects and causes disease throughout life without the need for significant antigenic change.
  • The virus encodes nonstructural protein 1 (NS1) and NS2, which are known to suppress type I interferon (IFN) production and signaling.
  • In the present study, we monitored the maturation of human monocyte-derived myeloid dendritic cells (DC) following inoculation with recombinant RSVs bearing deletions of the NS1 and/or NS2 proteins and expressing enhanced green fluorescent protein.
  • Deletion of the NS1 protein resulted in increased expression of cell surface markers of DC maturation and an increase in the expression of multiple cytokines and chemokines.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Cell Mol Biol. 2004 Jun;30(6):893-900 [14722224.001]
  • [Cites] J Immunol. 2004 Sep 1;173(5):3408-17 [15322205.001]
  • [Cites] N Engl J Med. 1979 Mar 8;300(10):530-4 [763253.001]
  • [Cites] Nature. 1980 Apr 10;284(5756):555-6 [6245367.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Mar 13;135(2):397-402 [3457562.001]
  • [Cites] Am J Pathol. 1990 Mar;136(3):593-608 [2156431.001]
  • [Cites] Vaccine. 1990 Oct;8(5):497-502 [2251875.001]
  • [Cites] J Infect Dis. 1991 Apr;163(4):693-8 [2010624.001]
  • [Cites] J Immunol. 1991 Dec 15;147(12):4307-12 [1753101.001]
  • [Cites] J Immunol. 1992 Jul 15;149(2):735-42 [1378080.001]
  • [Cites] Biochim Biophys Acta. 1994 Apr 5;1197(1):63-93 [8155692.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3821-35 [7706722.001]
  • [Cites] Immunology. 1995 Jul;85(3):364-72 [7558123.001]
  • [Cites] J Exp Med. 1995 Nov 1;182(5):1545-56 [7595224.001]
  • [Cites] J Clin Invest. 1995 Nov;96(5):2445-53 [7593633.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11563-7 [8524804.001]
  • [Cites] J Infect Dis. 1996 Sep;174(3):456-62 [8769600.001]
  • [Cites] J Infect Dis. 1997 Mar;175(3):497-504 [9041319.001]
  • [Cites] J Immunol. 2007 Jul 1;179(1):673-81 [17579090.001]
  • [Cites] J Biol Chem. 2007 Jul 13;282(28):20053-7 [17502368.001]
  • [Cites] Immunity. 2007 Aug;27(2):240-52 [17723216.001]
  • [Cites] Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):425-33 [17683972.001]
  • [Cites] Vaccine. 2007 Oct 16;25(42):7372-8 [17868959.001]
  • [Cites] Viral Immunol. 2007 Dec;20(4):531-40 [18158727.001]
  • [Cites] J Virol. 2008 Mar;82(5):2040-55 [17928346.001]
  • [Cites] J Gen Virol. 2005 Jun;86(Pt 6):1645-57 [15914842.001]
  • [Cites] Blood. 2005 Jul 1;106(1):216-23 [15790784.001]
  • [Cites] J Virol. 2005 Jul;79(14):9315-9 [15994826.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):637-50 [16129706.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):5904-11 [16237083.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1600-8 [16424189.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1528-36 [16239433.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Mar;34(3):320-9 [16284360.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2392-9 [16293598.001]
  • [Cites] J Virol. 2006 Apr;80(7):3416-27 [16537609.001]
  • [Cites] Int Arch Allergy Immunol. 2006;140(1):53-72 [16534219.001]
  • [Cites] J Virol. 2006 May;80(10):5032-40 [16641294.001]
  • [Cites] J Virol. 2006 Jun;80(12):5958-67 [16731934.001]
  • [Cites] J Leukoc Biol. 2006 Jun;79(6):1286-94 [16624932.001]
  • [Cites] J Virol. 2006 Jul;80(13):6295-304 [16775317.001]
  • [Cites] J Virol. 2006 Aug;80(16):8151-7 [16873271.001]
  • [Cites] Eur J Immunol. 2006 Jul;36(7):1827-36 [16783851.001]
  • [Cites] Immunity. 2006 Sep;25(3):373-81 [16979569.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3792-800 [16917011.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):171-80 [17190836.001]
  • [Cites] J Mol Biol. 2007 Feb 16;366(2):525-39 [17174979.001]
  • [Cites] J Virol. 2007 Feb;81(4):1786-95 [17151097.001]
  • [Cites] J Virol. 2007 Apr;81(7):3428-36 [17251292.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):59-69 [17334966.001]
  • [Cites] Virology. 2007 Aug 15;365(1):144-56 [17459446.001]
  • [Cites] J Virol. 2003 Aug;77(15):8426-39 [12857912.001]
  • [Cites] J Virol. 2003 Aug;77(16):8661-8 [12885884.001]
  • [Cites] J Virol. 2003 Sep;77(17):9156-72 [12915532.001]
  • [Cites] J Virol. 2003 Oct;77(20):11201-11 [14512568.001]
  • [Cites] Virology. 2003 Nov 10;316(1):41-54 [14599789.001]
  • [Cites] J Infect Dis. 2003 Dec 1;188(11):1630-8 [14639532.001]
  • [Cites] J Virol. 2004 Apr;78(8):4363-9 [15047850.001]
  • [Cites] JAMA. 1999 Oct 20;282(15):1440-6 [10535434.001]
  • [Cites] Eur J Immunol. 1999 Nov;29(11):3596-602 [10556814.001]
  • [Cites] J Exp Med. 2000 May 15;191(10):1777-88 [10811870.001]
  • [Cites] J Virol. 2000 Aug;74(15):7127-36 [10888653.001]
  • [Cites] Virology. 2000 Jul 20;273(1):210-8 [10891423.001]
  • [Cites] J Virol. 2000 Oct;74(19):9317-21 [10982380.001]
  • [Cites] Eur J Immunol. 2000 Oct;30(10):2741-50 [11069053.001]
  • [Cites] Nat Immunol. 2000 Nov;1(5):398-401 [11062499.001]
  • [Cites] J Virol. 2001 Dec;75(24):12128-40 [11711604.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2913-21 [11929782.001]
  • [Cites] Int Immunol. 2002 Apr;14(4):367-80 [11934873.001]
  • [Cites] Cancer Immunol Immunother. 2002 May;51(3):139-44 [11941452.001]
  • [Cites] J Virol. 2002 Oct;76(20):10109-21 [12239285.001]
  • [Cites] Biochem J. 2002 Oct 1;367(Pt 1):145-55 [12084011.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):2797-801 [12626527.001]
  • [Cites] J Infect Dis. 2003 Apr 1;187(7):1126-36 [12660927.001]
  • [Cites] Immunology. 2003 May;109(1):49-57 [12709017.001]
  • [Cites] Eur J Immunol. 2003 Jun;33(6):1677-85 [12778486.001]
  • [Cites] J Virol. 1997 Jul;71(7):4944-53 [9188557.001]
  • [Cites] Mamm Genome. 1997 Aug;8(8):581-2 [9250865.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):245-52 [9521319.001]
  • [Cites] J Immunol. 1998 May 1;160(9):4298-304 [9574532.001]
  • [Cites] J Virol. 1998 Jun;72(6):4756-64 [9573240.001]
  • [Cites] J Virol. 1999 Jan;73(1):466-73 [9847352.001]
  • [Cites] Cell Death Differ. 1999 Feb;6(2):99-104 [10200555.001]
  • [Cites] Science. 1999 Jun 11;284(5421):1835-7 [10364556.001]
  • [Cites] Nat Med. 1999 Aug;5(8):919-23 [10426316.001]
  • [Cites] Eur J Immunol. 1999 Sep;29(9):2769-78 [10508251.001]
  • [Cites] J Virol. 2005 May;79(9):5353-62 [15827150.001]
  • [Cites] J Virol. 2005 May;79(9):5507-15 [15827165.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1749-59 [15858184.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):257-64 [15101709.001]
  • (PMID = 18562519.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Cytokines; 0 / Viral Nonstructural Proteins; 147336-22-9 / Green Fluorescent Proteins; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2519638
  •  go-up   go-down


35. Váróczy L, Gergely L, Miltényi Z, Aleksza M, Illés A: Can CD3+/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's lymphoma patients? Immunol Lett; 2005 Feb 15;97(1):155-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can CD3+/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's lymphoma patients?
  • The immune system has several mechanisms to fight against developing malignant cell clones in the host, one of them is the activated T-cell response.
  • Our aim was to determine, how the ratio of activated T cells change in the peripheral blood of non-Hodgkin's lymphoma (NHL) patients during the periods of polychemotherapy.
  • We suppose that investigation of CD3+/HLA-DR+ activated T cells might be a promising method to determine the prognostics of lymphoma patients.
  • [MeSH-major] Antigens, CD3 / immunology. HLA-DR Antigens / immunology. Lymphoma, Non-Hodgkin / diagnosis. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626488.001).
  • [ISSN] 0165-2478
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / HLA-DR Antigens
  •  go-up   go-down


36. Zhou Y, Li Q, Meng HX, Wang YF, Yu Z, Qiu LG: [The expression and clinical significance of early differentiation antigens in acute leukemia]. Zhonghua Nei Ke Za Zhi; 2005 Jan;44(1):46-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression and clinical significance of early differentiation antigens in acute leukemia].
  • OBJECTIVE: To evaluate the expression and clinical significance of early differentiation antigens of hematopoietic cells CD(34), CD(90) and CD(133) in acute leukemia (AL).
  • The expression of CD(133) antigen was highly correlated with CD(133) mRNA expression in both of the normal control donors and AL patients (r = 0.932, P < 0.01). (2) The positive rates of CD(34), CD(90) and CD(133) in all AL patients were 63.2%, 7.9% and 42.1%, respectively.
  • Positive expression of CD(133) in AML-M(4) was significantly higher than that in other AML subtypes (P < 0.01).
  • The positive rate of CD(34) in B-ALL was much higher than that in T-ALL (P < 0.05). (3) CD(133) expression in AML was significantly correlated with the expression of CD(34) and HLA-DR (P < 0.01). (4) The expression of CD(34), CD(90) and CD(133) was not associated with the clinical prognostic factors such as cytogenetic or molecular aberrations, initial peripheral blood WBC counts, lactate dehydrogenase level, multiple drug resistant expression and age. (5) There was a trend toward lower completely remission (CR) rate and overall survival rate in CD(34), CD(90) and CD(133) positive cases, but only CD(34)(+)/CD(133)(+) cases had significant lower CR rate than negative ones (P < 0.05).
  • CD(133)/CD(34) co-expression might provide adverse prognostic stratification of acute leukemia.
  • [MeSH-major] Antigens, CD34 / metabolism. Antigens, Thy-1 / metabolism. Glycoproteins / metabolism. Leukemia, Myeloid, Acute / metabolism. Peptides / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD. Child. Female. Humans. Male. Middle Aged. Prognosis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15769398.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Thy-1; 0 / Glycoproteins; 0 / Peptides; 0 / RNA, Messenger
  •  go-up   go-down


37. Jacyk WK, Grayson W, Dinkel JE, Requena L: Pagetoid reticulosis with CD30 positivity and cytotoxic/suppressor cells. J Cutan Pathol; 2007 Aug;34(8):644-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pagetoid reticulosis (PR) is a low-grade primary cutaneous T-cell lymphoma that usually presents as a solitary, slowly enlarging erythematous or hyperkeratotic plaque on the distal areas of the extremities.
  • Histopathologically, it is characterized by a dense, band-like infiltrate of atypical lymphocytes with prominent epidermotropism within a hyperplastic epidermis, and immunophenotypic studies show in most cases, a CD4-positive T-helper phenotype for the neoplastic lymphocytes.
  • We describe an African man with a more than 20-year history of an acral lesion of PR, which was histopathologically characterized by lymphocyte immunophenotype consisting of CD8- and CD30-positive cells.
  • We discuss the differential diagnosis with other primary cutaneous lymphoproliferative disorders showing similar immunophenotype.
  • This case shows that CD30-positive PR should be included as a rare variant within the spectrum of CD30-positive primary cutaneous lymphoproliferative disorders.
  • As in other primary cutaneous CD30-positive lymphoproliferative processes, lesions of CD30-positive PR show an indolent course and a benign biological behavior.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphatic Diseases / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / pathology. T-Lymphocytes, Cytotoxic / pathology
  • [MeSH-minor] Adult. Biomarkers / metabolism. Biopsy. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / pathology. Humans. Immunophenotyping. Male

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640236.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers
  •  go-up   go-down


38. Graux C, Stevens-Kroef M, Lafage M, Dastugue N, Harrison CJ, Mugneret F, Bahloula K, Struski S, Grégoire MJ, Nadal N, Lippert E, Taviaux S, Simons A, Kuiper RP, Moorman AV, Barber K, Bosly A, Michaux L, Vandenberghe P, Lahortiga I, De Keersmaecker K, Wlodarska I, Cools J, Hagemeijer A, Poirel HA, Groupe Francophone de Cytogénétique Hématologique, Belgian Cytogenetic Group for Hematology and Oncology: Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. Leukemia; 2009 Jan;23(1):125-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.
  • In this multicentric study we collected 27 cases of NUP214-ABL1-positive T-ALL.
  • An associated abnormality involving TLX1 or TLX3 was found in all investigated cases.
  • In addition, intrachromosomal amplification (small hsr) was identified either as the only change or in association with episomes in four cases and two T-ALL cell lines (PEER and ALL-SIL).
  • [MeSH-major] Gene Amplification. Leukemia-Lymphoma, Adult T-Cell / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Child. Child, Preschool. Female. Homeodomain Proteins / genetics. Humans. Male. Middle Aged. Plasmids. Proto-Oncogene Proteins / genetics. Sex Factors. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18923437.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NUP214-ABL1 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / TLX3 protein, human; 143275-75-6 / TLX1 protein, human
  • [Investigator] Barin C; Berger R; Bilhou-Nabera C; Cabrol C; Callet-Bauchu E; Cornillet-Lefebvre P; Laï JL; Lefebvre C; Luquet I; Perot C; Radford-Weiss I; Speleman F; Cauwelier B; Talmant P; Terré C; Tigaud I; Van DenAkker J; Viguié F
  •  go-up   go-down


39. Shinomiya N, Koike Y, Koyama H, Takayama E, Habu Y, Fukasawa M, Tanuma S, Seki S: Analysis of the susceptibility of CD57 T cells to CD3-mediated apoptosis. Clin Exp Immunol; 2005 Feb;139(2):268-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After stimulation with anti-CD3 antibody in vitro, CD57(+) T cells showed a greater susceptibility to apoptosis than CD57(-)alphabetaT cell receptor (TCR)(+) T cells (regular alphabeta T cells).
  • CD57(+) T cells display a biased expansion of a few Vbeta T cell fractions in individuals, but such Vbeta T cells were not specifically susceptible to CD3-mediated apoptosis.
  • Although the CD3epsilon expression levels were similar in both T cell subsets, the CD3zeta level of CD57(+) T cells was significantly higher than that of regular T cells.
  • [MeSH-minor] Adult. Antibodies / pharmacology. Antigens, CD95 / analysis. Antigens, CD95 / immunology. Apoptosis / immunology. Caspase 3. Caspases / metabolism. Cells, Cultured. Fas Ligand Protein. Humans. Immunoglobulin epsilon-Chains / analysis. Immunoglobulin gamma-Chains / analysis. Inhibitor of Apoptosis Proteins. Membrane Glycoproteins / analysis. Membrane Glycoproteins / immunology. Microtubule-Associated Proteins / analysis. Microtubule-Associated Proteins / immunology. Neoplasm Proteins. Receptors, Antigen, T-Cell, alpha-beta / immunology. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 1999 Nov;35(5-6):545-54 [10609792.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1837-45 [9885904.001]
  • [Cites] Immunol Rev. 2000 Apr;174:35-46 [10807505.001]
  • [Cites] Immunol Rev. 2000 Apr;174:135-49 [10807513.001]
  • [Cites] J Immunol. 2000 Jun 1;164(11):5652-8 [10820240.001]
  • [Cites] Eur J Immunol. 2000 Jul;30(7):1919-28 [10940881.001]
  • [Cites] Hepatology. 2000 Nov;32(5):962-9 [11050046.001]
  • [Cites] Hum Immunol. 2000 Sep;61(9):908-16 [11053634.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):74-80 [11205921.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):947s-957s [11300496.001]
  • [Cites] J Immunol. 2001 Jun 1;166(11):6578-84 [11359810.001]
  • [Cites] Immunology. 2001 Jul;103(3):281-90 [11454057.001]
  • [Cites] Clin Exp Immunol. 2002 Jun;128(3):453-9 [12109440.001]
  • [Cites] Clin Exp Immunol. 2002 Oct;130(1):162-8 [12296868.001]
  • [Cites] J Immunol. 2002 Dec 1;169(11):6127-32 [12444115.001]
  • [Cites] Immunology. 2003 Feb;108(2):211-9 [12562330.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2711-20 [12433688.001]
  • [Cites] J Immunol. 2003 Aug 15;171(4):1901-8 [12902492.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10913-8 [12960397.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4020-7 [14530322.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6550-7 [15153469.001]
  • [Cites] Immunology. 2004 Sep;113(1):35-43 [15312134.001]
  • [Cites] J Immunol. 1981 Sep;127(3):1024-9 [6790607.001]
  • [Cites] J Immunol. 1983 Oct;131(4):1822-6 [6413578.001]
  • [Cites] Transplantation. 1985 Jan;39(1):25-9 [3880961.001]
  • [Cites] J Immunol. 1986 Oct 1;137(7):2180-9 [2944951.001]
  • [Cites] J Immunol. 1986 Nov 1;137(9):2808-13 [2944964.001]
  • [Cites] J Immunol. 1988 Dec 1;141(11):3791-7 [2903195.001]
  • [Cites] Annu Rev Cell Biol. 1990;6:403-31 [2275818.001]
  • [Cites] J Immunol. 1991 Aug 15;147(4):1214-21 [1831220.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1492-6 [1346934.001]
  • [Cites] Nature. 1992 Mar 26;356(6367):314-7 [1372394.001]
  • [Cites] Arthritis Rheum. 1993 May;36(5):608-12 [7683880.001]
  • [Cites] Curr Opin Immunol. 1993 Jun;5(3):324-33 [8347295.001]
  • [Cites] Int Rev Immunol. 1994;11(1):61-102 [8057045.001]
  • [Cites] Eur J Immunol. 1994 Nov;24(11):2882-8 [7525310.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):438-41 [7530335.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):441-4 [7530336.001]
  • [Cites] Nature. 1995 Feb 2;373(6513):444-8 [7530337.001]
  • [Cites] J Exp Med. 1995 Feb 1;181(2):781-6 [7530763.001]
  • [Cites] J Immunol. 1995 Apr 15;154(8):3806-13 [7706720.001]
  • [Cites] EMBO J. 1995 Mar 15;14(6):1129-35 [7536672.001]
  • [Cites] J Exp Med. 1995 May 1;181(5):1881-6 [7722462.001]
  • [Cites] J Immunol. 1995 Jun 1;154(11):6182-90 [7538544.001]
  • [Cites] Mech Ageing Dev. 1996 Jul 5;88(1-2):25-38 [8804091.001]
  • [Cites] Mech Ageing Dev. 1997 Mar;94(1-3):123-34 [9147365.001]
  • [Cites] Hepatology. 1997 Aug;26(2):301-9 [9252138.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] J Clin Immunol. 1997 Sep;17(5):420-9 [9327342.001]
  • [Cites] J Immunol. 1998 Feb 15;160(4):1627-37 [9469419.001]
  • [Cites] Clin Exp Immunol. 1998 Feb;111(2):345-52 [9486402.001]
  • [Cites] Scand J Immunol. 1998 Mar;47(3):254-62 [9519864.001]
  • [Cites] Br J Haematol. 1998 Mar;100(4):784-92 [9531350.001]
  • [Cites] Clin Cancer Res. 1996 Jan;2(1):161-73 [9816103.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4771-7 [9845544.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] Blood Rev. 1999 Dec;13(4):230-40 [10741898.001]
  • (PMID = 15654825.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD3; 0 / Antigens, CD57; 0 / Antigens, CD95; 0 / BIRC5 protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Immunoglobulin epsilon-Chains; 0 / Immunoglobulin gamma-Chains; 0 / Inhibitor of Apoptosis Proteins; 0 / Membrane Glycoproteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Receptors, Antigen, T-Cell, alpha-beta; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1809296
  •  go-up   go-down


40. Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin R: Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant; 2006 Jan;12(1 Suppl 2):37-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?
  • Acute and chronic graft-versus-host disease (GVHD) continue to be major limitations to successful hematopoietic stem cell transplantation.
  • Photopheresis is currently indicated and Food and Drug Administration-approved for the treatment of skin manifestations of cutaneous T-cell lymphoma, where the response rate has proved to be considerably high.
  • Extracorporeal photochemotherapy has been evaluated in small cohorts of patients with both acute and chronic GVHD.
  • In steroid-refractory acute GVHD of the skin and liver, the reported response rate is more than 60%, especially in patients with less severe forms of the disease.
  • All of these results indicate activity of extracorporeal photopheresis in acute and chronic GVHD, which warrants further evaluation of this therapy in well-designed, prospective, controlled studies.
  • [MeSH-major] Graft vs Host Disease / therapy. Photopheresis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Chronic Disease. Cohort Studies. Disease-Free Survival. Humans. Male. Middle Aged. Neoplasms / complications. Neoplasms / mortality. Neoplasms / therapy. Remission Induction. Retrospective Studies

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399600.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Oba T, Suzuki R, Miyamura K, Kodera Y: Huge mass of cutaneous-type adult T-cell leukemia which responded to interferon gamma. Intern Med; 2007;46(3):147
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge mass of cutaneous-type adult T-cell leukemia which responded to interferon gamma.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268135.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


42. Nakamura S, Ye H, Bacon CM, Goatly A, Liu H, Kerr L, Banham AH, Streubel B, Yao T, Tsuneyoshi M, Savio A, Takeshita M, Dartigues P, Ruskoné-Fourmestraux A, Matsumoto T, Iida M, Du MQ: Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma. Clin Cancer Res; 2008 May 15;14(10):3002-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.
  • PURPOSE: The pathogenesis and clinical heterogeneity of gastric diffuse large B-cell lymphoma (DLBCL) are poorly understood.
  • We have comprehensively investigated the incidence and clinical significance of lymphoma-associated chromosomal translocations, particularly those involving the immunoglobulin heavy chain (IGH) gene locus, in a large series of gastric DLBCL.
  • EXPERIMENTAL DESIGN: One hundred forty-one cases of primary gastric DLBCL [58 with mucosa-associated lymphoid tissue (MALT) lymphoma and 83 without MALT lymphoma] were enrolled.
  • In positive cases, additional fluorescence in situ hybridization was done with appropriate probes for potential partner genes.
  • Cases were classified into germinal center B-cell-like (GCB) or non-GCB subgroups by immunophenotyping with CD10, BCL6, and MUM1.
  • RESULTS: Translocations involving IGH were detected in 36 (32%) of 111 cases; their partner genes included BCL6 (n = 10), c-MYC (n = 5), and FOXP1 (n = 3) but remained unknown in the remaining 18 cases. t(14;18)/IGH-BCL2, t(14;18)/IGH-MALT1, and t(1;14)/BCL10-IGH were not detected in any case. t(11;18)/API2-MALT1 was detected in none of the cases, except for one case of DLBCL with MALT lymphoma, which showed positive signals only in MALT lymphoma cells.
  • IGH-involved translocation was associated with younger age but not with any other clinicopathologic factors including GCB or non-GCB immunophenotypes.
  • [MeSH-major] Immunoglobulin Heavy Chains / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Stomach Neoplasms / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445693.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


43. Dietel V, Bührdel P, Hirsch W, Körholz D, Kiess W: Cerebral sinus occlusion in a boy presenting with asparaginase-induced hypertriglyceridemia. Klin Padiatr; 2007 Mar-Apr;219(2):95-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cerebral sinus thrombosis is a rare but severe complication during treatment for acute lymphoblastic leukaemia (ALL).
  • Hypertriglyceridemia has - albeit very rarely - also been associated with asparaginase therapy.
  • Here we describe a 15-year-old boy who presented with clinical symptoms and radiologic findings of a cerebral sinus thrombosis.
  • [MeSH-major] Antineoplastic Agents / toxicity. Antineoplastic Combined Chemotherapy Protocols / toxicity. Asparaginase / toxicity. Hypertriglyceridemia / chemically induced. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Polyethylene Glycols / toxicity. Sinus Thrombosis, Intracranial / chemically induced

  • MedlinePlus Health Information. consumer health - Triglycerides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405075.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Heparin, Low-Molecular-Weight; 0 / Hypolipidemic Agents; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; EC 3.5.1.1 / Asparaginase; Y9449Q51XH / Bezafibrate
  •  go-up   go-down


44. Kletting P, Kull T, Reske SN, Glatting G: Comparing time activity curves using the Akaike information criterion. Phys Med Biol; 2009 Nov 7;54(21):N501-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Antigens, CD / chemistry. Cell Adhesion Molecules / chemistry. Female. Humans. Indium Radioisotopes / pharmacokinetics. Kinetics. Leukemia, Myeloid, Acute / radiotherapy. Male. Middle Aged. Models, Statistical. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Radiopharmaceuticals / pharmacokinetics. Yttrium Radioisotopes / pharmacokinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820266.001).
  • [ISSN] 1361-6560
  • [Journal-full-title] Physics in medicine and biology
  • [ISO-abbreviation] Phys Med Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Indium Radioisotopes; 0 / Radiopharmaceuticals; 0 / Yttrium Radioisotopes
  •  go-up   go-down


45. Tsartsidze E, Betaneli M: Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma. Georgian Med News; 2006 May;(134):107-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of immunophenotype in aggressive non-Hodgkin's lymphoma.
  • The purpose of the study was to evaluate prognostic value of immunophenotype in aggressive Non-Hodgkin's lymphoma.
  • 87 patients with immunohistologically confirmed diagnosis of aggressive Non-Hodgkin's lymphoma according to the WHO classification (2001) were under observation.
  • Overall survival was calculated from the date of diagnosis to the last follow-up or death regardless of the cause.
  • 17 patients out of 87 were diagnosed as T-cell lymphomas.
  • Overall survival in patients with IPI greater than 2 (poor prognosis) was shorter for T-cell lymphomas (7,6 months) in comparison with B-cell lymphomas (17,3 months) (p<0,001).
  • T-cell phenotype should be considered as an independent factor that strongly influences the survival for patients with diagnosis of aggressive non-Hodgkin's lymphomas.
  • Besides petipherial T-cell lymphomas occurs more frequently in the elderly, with advanced stage, frequent extranodal site involvement, and often detected high level of LDH compared with B-cell lymphomas.
  • [MeSH-major] B-Lymphocytes / immunology. Immunophenotyping. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / mortality. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Humans. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16783081.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


46. Ständer H, Neugebauer F, Schneider SW, Luger TA, Schiller M: Extracorporeal photopheresis with permanent subcutaneous right atrial catheters. J Dtsch Dermatol Ges; 2007 Dec;5(12):1112-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As this approach is not always feasible in older patients and patients with graft-versus-host disease, central venous catheters play an increasing role in providing long-term vascular access for ECP.However, not all catheters are able to deliver the minimum flow rate of 7 ml/min for ECP.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blood Flow Velocity. Equipment Design. Equipment Failure Analysis. Female. Graft vs Host Disease / drug therapy. Humans. Hydrostatic Pressure. In Vitro Techniques. Lymphoma, T-Cell, Cutaneous / drug therapy. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17888008.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Demirkan F, Alacacioglu I, Piskin O, Ozsan HG, Akinci B, Ozcan AM, Yavuzsen T, Yuksel E, Undar B: The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey. Leuk Lymphoma; 2007 Jul;48(7):1372-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey.
  • In a retrospective analysis of 113 patients with primary myelodysplastic syndromes (MDS) diagnosed according to French-American-British (FAB) classification, we evaluated the prognostic impact of FAB and World Health Organisation (WHO) classifications, International Prognostic Scoring System (IPSS), and other clinical and laboratory variables.
  • At a median follow-up of 24 months, 22 patients (19.5 %) transformed to acute myelogenous leukaemia (AML).
  • In WHO classification, significant differences were observed in both OS and leukaemia free survival (LFS) between patients with RA/RARS and refractory cytopenia with multi-lineage dysplasia/refractory cytopenia with multi-lineage dysplasia and ringed sideroblasts (RCMD/RS-RCMD) (p = 0.0001).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Classification. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis. Turkey / epidemiology. World Health Organization


48. Jeang KT: Progress, challenges, and responsibilities in retrovirology. Retrovirology; 2005;2:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this editorial, Retrovirology's choice for best basic science "retrovirus paper of the year" and a perspective on challenges and responsibilities facing HIV-1 and HTLV-I research are presented.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell. Research
  • [MeSH-minor] Animals. Disease Models, Animal. HIV Infections / drug therapy. HIV Infections / epidemiology. HIV Infections / prevention & control. HIV-1 / pathogenicity. Human T-lymphotropic virus 1. Humans. Proteins / metabolism. Proteins / therapeutic use

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Feb 26;427(6977):848-53 [14985764.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] Retrovirology. 2004;1:9 [15169567.001]
  • [Cites] Retrovirology. 2004;1:2 [15169555.001]
  • [Cites] Retrovirology. 2004;1:46 [15620346.001]
  • (PMID = 15644139.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteins; 0 / TRIM5(alpha) protein, rhesus monkey
  • [Other-IDs] NLM/ PMC544867
  •  go-up   go-down


49. Lee Y, Lee KW, Kim JH, Bang SM, Lee JS, Park BB, Kim WS, Suh C, Kang JH, Ryoo BY, Lee JH, Shin DB: Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma. Korean J Intern Med; 2008 Mar;23(1):30-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma.
  • BACKGROUND/AIMS: Epstein-Barr virus (EBV) is involved in the pathogenesis of angioimmunoblastic T-cell lymphoma (AILT), but its precise role and prognostic impact are not clear.
  • This study aimed to evaluate the incidence of EBV-postitivity in the tumor and bone marrow (BM) samples from AILT patients, and their correlations with the clinical variables and patient survival.
  • RESULTS: Among the 27 tumor specimens, ten (37%) were EBV-positive.
  • In 13 (48%) patients, gross tumor involvement was recognized by hematoxylin-eosin staining at the time of diagnosis.
  • Among the 10 patients who had additional BM slides available, there were 3 with BM involvement, and none showed EBV positive results on ISH.
  • EBV PCR of the BM mononuclear cells revealed one-positive case among 8 patients.
  • [MeSH-major] Herpesvirus 4, Human / isolation & purification. Immunoblastic Lymphadenopathy / virology. Lymphoma, T-Cell / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow / virology. DNA, Viral / isolation & purification. Female. Humans. In Situ Hybridization. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):661-9 [10666395.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):860-8 [17509983.001]
  • [Cites] Am J Clin Pathol. 2000 Aug;114(2):236-47 [10941339.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):368-79 [11888076.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):805-11 [12153168.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] J Korean Med Sci. 2004 Apr;19(2):229-33 [15082896.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Int J Cancer. 1976 Feb 15;17(2):177-81 [175027.001]
  • [Cites] Blood. 1991 Feb 15;77(4):799-808 [1847084.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1789-95 [1373088.001]
  • [Cites] Blood. 1992 Jul 15;80(2):484-91 [1320954.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1804-12 [1327284.001]
  • [Cites] Histopathology. 1993 Feb;22(2):145-9 [8384155.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):659-64 [8664186.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1192-6 [16154842.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:260-6 [16304390.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):466-75; quiz 527 [16931587.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):716-22 [17454629.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • (PMID = 18363277.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2686953
  •  go-up   go-down


50. Khositseth S, Matas A, Cook ME, Gillingham KJ, Chavers BM: Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report. Transplantation; 2005 Apr 27;79(8):958-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Induction immunosuppressive therapy with the anti-T-cell antibody Thymoglobulin decreases the incidence of acute rejection in adult kidney transplant (KTx) recipients, but limited data are available for pediatric KTx recipients.
  • RESULTS: Overall, the incidence of acute rejection was lower in Thymoglobulin recipients versus ATGAM recipients (33% vs. 50%, P=0.02).
  • Epstein-Barr virus (EBV) infection was higher in Thymoglobulin recipients versus ATGAM recipients (8% vs. 3%, P=0.002).
  • But the two groups did not significantly differ in patient and graft survival rates, incidence of chronic rejection, EBV lymphoma, or other infection.
  • CONCLUSIONS: Thus, Thymoglobulin induction was associated with a decreased incidence of acute rejection and an increased incidence of EBV infection in pediatric KTx recipients.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849550.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK13083
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum
  •  go-up   go-down


51. Tardío JC, Moreno A, Pérez C, Hernández-Rivas JA, López-Carreira M: Primary laryngeal T/NK-cell lymphoma, nasal-type: an unusual location for an aggressive subtype of extranodal lymphoma. Eur Arch Otorhinolaryngol; 2008 Jun;265(6):705-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary laryngeal T/NK-cell lymphoma, nasal-type: an unusual location for an aggressive subtype of extranodal lymphoma.
  • Most of them are extramedullary plasmocytomas, diffuse large B-cell lymphomas, or MALT-type marginal zone B-cell lymphomas.
  • T- or NK-cell lymphomas have rarely been reported in this location.
  • The diagnosis of laryngeal lymphomas is a challenge, due to the absence of clinical and gross differential criteria.
  • We present hereby a primary laryngeal T/NK-cell lymphoma, nasal-type.
  • Polychemotherapy was administrated with initial partial response, but rapid local progression and exitus followed six months after the diagnosis.
  • The extranodal T/NK-cell lymphoma, nasal-type is a very aggressive subtype of extranodal lymphoma, usually located in the nasal cavity or in nearby sites.
  • The prognosis of extranasal cases of this type of lymphoma is poor, even when they are diagnosed in localized stages.
  • [MeSH-major] Killer Cells, Natural / pathology. Laryngeal Neoplasms / diagnosis. Lymphoma, T-Cell, Peripheral / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Fatal Outcome. Humans. Laryngoscopy. Male. Severity of Illness Index. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Otolaryngol. 1996 Sep-Oct;17(5):332-4 [8870939.001]
  • [Cites] Pathol Res Pract. 1995 Mar;191(2):130-8 [7567682.001]
  • [Cites] Cancer. 1996 May 15;77(10):2137-49 [8640683.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Cancer. 1979 Apr;43(4):1527-32 [445348.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Sep;121(3):335-6 [10471889.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):1037-40 [9738818.001]
  • [Cites] Leuk Lymphoma. 1999 Oct;35(3-4):397-401 [10706465.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:267-77 [16304391.001]
  • [Cites] Leuk Lymphoma. 2003 Jun;44(6):1053-7 [12854909.001]
  • [Cites] Laryngoscope. 1997 Nov;107(11 Pt 1):1502-6 [9369397.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:331-7 [17124080.001]
  • [Cites] J Laryngol Otol. 1989 Oct;103(10):955-60 [2685150.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):821-9 [9217183.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1723-31 [9473239.001]
  • [Cites] Hum Pathol. 1990 Oct;21(10):1041-50 [2210727.001]
  • [Cites] Head Neck. 2001 Aug;23(8):625-8 [11443744.001]
  • (PMID = 17955253.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


52. Rymkiewicz G, Ptaszyński K, Walewski J, Błachnio K, Swoboda P, Gos M, Paszkiewicz-Kozik E, Woroniecka R, Pieńkowska-Grela B, Czarnocka M, Janik P: Unusual cyclin D1 positive marginal zone lymphoma of mediastinum. Med Oncol; 2006;23(3):423-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual cyclin D1 positive marginal zone lymphoma of mediastinum.
  • We report a case of 43-yr-old Caucasian female with an unusual, cyclin D1 positive marginal zone lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) type of the mediastinum.
  • They occur mainly in Asian females with a history of coexisting autoimmune disease.
  • The diagnosis was based on histopathological examination only.
  • Our final diagnosis of MZL was made by combined evaluation of histopathology (HP), immunohistochemistry (IH), flow cytometry (FCM), fluorescence in situ hybridization (FISH), and molecular biology studies.
  • We found a positive cyclin D1 reaction by IH and cyclin D1 mRNA (CCND1) overexpression by reverse transcription polymerase chain reaction (RT-PCR).
  • Very high cyclin D1 to beta-actin mRNA ratio in this case was comparable with the ratio, characteristic for mantle cell lymphoma (MCL).
  • However, there was no translocation t(11;14) found by FISH and an immunophenotype by IH and FCM was consistent with MZL ruling out MCL diagnosis.
  • In addition, our case differs from other, previously reported thymic MZL lymphoma cases by no autoimmune disease association, Caucasian origin, and the absence of the plasmacytic differentiation on both HP/IH.
  • [MeSH-major] Cyclin D1 / biosynthesis. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell, Marginal Zone / metabolism. Mediastinal Neoplasms / metabolism
  • [MeSH-minor] Adult. Female. Flow Cytometry / methods. Humans. Immunohistochemistry / methods. Immunophenotyping. In Situ Hybridization, Fluorescence / methods. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / pathology. Models, Biological. Translocation, Genetic


53. Hui D, Proctor B, Donaldson J, Shenkier T, Hoskins P, Klasa R, Savage K, Chhanabhai M, Gascoyne RD, Connors JM, Sehn LH: Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma; 2010 Sep;51(9):1658-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.
  • We sought to re-examine the prognostic utility of (1) the number of extranodal sites of disease involvement, and (2) a primary extranodal presentation in patients with DLBCL treated with immunochemotherapy.
  • In the R-CHOP group, extranodal involvement as defined by the International Prognostic Index (>or=2 sites) was not prognostic on multivariate analysis, but the presence of any extranodal involvement (>or=1 site) was associated with decreased progression-free survival (HR 1.6, 95% CI 1.1-2.4, p = 0.024) and overall survival (HR 1.8, 95% CI 1.1-2.7, p = 0.011).
  • There was no difference in outcome between patients with primary extranodal and nodal DLBCL, and no primary site of involvement was associated with an inferior outcome.
  • In patients with DLBCL treated with R-CHOP, the presence of extranodal disease remains prognostic, whereas a primary extranodal presentation did not affect outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prognosis. Rituximab. Survival Rate. Tissue Distribution. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20795790.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


54. Kress AK, Schneider G, Pichler K, Kalmer M, Fleckenstein B, Grassmann R: Elevated cyclic AMP levels in T lymphocytes transformed by human T-cell lymphotropic virus type 1. J Virol; 2010 Sep;84(17):8732-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated cyclic AMP levels in T lymphocytes transformed by human T-cell lymphotropic virus type 1.
  • Human T-cell lymphotropic virus type 1 (HTLV-1), the cause of adult T-cell leukemia/lymphoma (ATLL), transforms CD4(+) T cells to permanent growth through its transactivator Tax.
  • HTLV-1-transformed cells share phenotypic properties with memory and regulatory T cells (T-reg).
  • This led us to determine cAMP levels in HTLV-1-transformed cells.
  • We found elevated cAMP concentrations as a consistent feature of all HTLV-1-transformed cell lines, including in vitro-HTLV-1-transformed, Tax-transformed, and patient-derived cells.
  • We found specific downregulation of the cAMP-degrading phosphodiesterase 3B (PDE3B) in HTLV-1-transformed cells, which was independent of Tax in transient expression experiments.
  • Overexpression of PDE3B led to a decrease of cAMP in HTLV-1-transformed cells.
  • Decreased expression of PDE3B was associated with inhibitory histone modifications at the PDE3B promoter and the PDE3B locus.
  • This shows that HTLV-1-transformed cells assume biological features of long-lived T-cell populations that potentially contribute to viral persistence.
  • [MeSH-major] Cell Transformation, Viral. Cyclic AMP / metabolism. HTLV-I Infections / metabolism. Human T-lymphotropic virus 1 / physiology. Leukemia-Lymphoma, Adult T-Cell / metabolism
  • [MeSH-minor] Cell Line, Transformed. Cells, Cultured. Cyclic Nucleotide Phosphodiesterases, Type 3 / genetics. Cyclic Nucleotide Phosphodiesterases, Type 3 / metabolism. Gene Products, tax / genetics. Gene Products, tax / metabolism. Humans. T-Lymphocytes / metabolism. T-Lymphocytes / virology

  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 1999 Sep 15;58(6):935-50 [10509746.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4458-62 [2873886.001]
  • [Cites] Cancer Sci. 2005 Aug;96(8):527-33 [16108835.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5938-51 [16155601.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6026-34 [16155609.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6035-46 [16155610.001]
  • [Cites] Int Immunol. 2006 Feb;18(2):269-77 [16361311.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4491-9 [16467195.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):488-520 [16968949.001]
  • [Cites] J Leukoc Biol. 2006 Oct;80(4):880-8 [16888088.001]
  • [Cites] Blood. 2006 Dec 15;108(13):3979-82 [16917009.001]
  • [Cites] J Virol. 2007 Mar;81(5):2524-30 [17151105.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):771-5 [17220874.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):936-40 [17237761.001]
  • [Cites] Cell. 2007 Feb 23;128(4):669-81 [17320505.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] J Exp Med. 2007 Jun 11;204(6):1303-10 [17502663.001]
  • [Cites] J Biol Chem. 2007 Jun 29;282(26):18750-7 [17449469.001]
  • [Cites] J Immunol. 2008 Jan 15;180(2):931-9 [18178833.001]
  • [Cites] J Gen Physiol. 2008 Apr;131(4):293-305 [18378798.001]
  • [Cites] Blood. 2008 May 1;111(9):4741-51 [18276843.001]
  • [Cites] Blood. 2000 Jan 1;95(1):30-8 [10607681.001]
  • [Cites] FEBS Lett. 2001 Sep 7;505(1):136-40 [11557056.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]
  • [Cites] Mol Cell Biol. 1985 Dec;5(12):3610-6 [3915782.001]
  • [Cites] Nature. 1988 Oct 20;335(6192):738-40 [3262832.001]
  • [Cites] J Virol. 1989 Apr;63(4):1604-11 [2538645.001]
  • [Cites] J Virol. 1989 Aug;63(8):3220-6 [2501514.001]
  • [Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994 Oct;10(10):1259-68 [7531462.001]
  • [Cites] J Exp Med. 1995 Mar 1;181(3):985-92 [7532686.001]
  • [Cites] Clin Diagn Lab Immunol. 1995 May;2(3):349-55 [7545080.001]
  • [Cites] J Virol. 1998 Jan;72(1):633-40 [9420268.001]
  • [Cites] Retrovirology. 2008;5:76 [18702816.001]
  • [Cites] FEBS Lett. 2008 Oct 29;582(25-26):3614-8 [18835269.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3788-97 [18689544.001]
  • [Cites] Retrovirology. 2008;5:100 [19014482.001]
  • [Cites] Int J Cancer. 2009 Nov 15;125(10):2375-82 [19544530.001]
  • [Cites] Virus Genes. 2001 Dec;23(3):263-71 [11778694.001]
  • [Cites] Blood. 2002 May 1;99(9):3383-9 [11964307.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):710-8 [12209131.001]
  • [Cites] Virology. 2003 Dec 5;317(1):136-45 [14675632.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2039-46 [15026341.001]
  • [Cites] J Virol. 2004 Sep;78(18):9814-9 [15331715.001]
  • [Cites] J Immunol. 1971 Nov;107(5):1489-92 [4330163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7 [6326131.001]
  • [Cites] Gan. 1984 Sep;75(9):752-5 [6094296.001]
  • [Cites] J Gen Virol. 1985 Aug;66 ( Pt 8):1825-9 [2991447.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 1;332(2):569-84 [15896717.001]
  • (PMID = 20573814.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE17718
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / tax protein, Human T-lymphotrophic virus 1; E0399OZS9N / Cyclic AMP; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 3; EC 3.1.4.17 / PDE3B protein, human
  • [Other-IDs] NLM/ PMC2918996
  •  go-up   go-down


55. Dulai MS, Park CY, Howell WD, Smyth LT, Desai M, Carter DM, Vogel H: CNS T-cell lymphoma: an under-recognized entity? Acta Neuropathol; 2008 Mar;115(3):345-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS T-cell lymphoma: an under-recognized entity?
  • The incidence of CNS lymphoma has increased significantly in the past 30 years, primarily in the elderly and immunocompromised.
  • While T-cell lymphomas comprise 15-20% of systemic lymphomas, they comprise less than 4% of primary CNS lymphomas, suggesting that they may be under-recognized compared to their systemic counterparts.
  • To investigate this, we studied brain biopsies from three patients who were diagnosed with T-cell lymphoma confined to the brain.
  • We compared these to biopsies from three patients who had reactive lymphoid infiltrates and who had clinical signs/symptoms and radiographic findings that were indistinguishable from the lymphoma group.
  • Biopsies from both the lymphoma group and reactive group showed considerable cytomorphologic heterogeneity.
  • Although one lymphoma case contained large atypical cells, the other two contained small, mature lymphocytes within a heterogeneous infiltrate of neoplastic and reactive inflammatory cells.
  • Surface marker aberrancies were present in two lymphoma cases, but this alone could not reliably diagnose T-cell lymphoma.
  • The proliferation index was not useful for differentiating lymphoma from reactive infiltrates.
  • In five of the six cases the diagnosis was most influenced by clonality studies for T-cell receptor-gamma gene rearrangements.
  • We conclude that because of the high degree of overlap in cytomorphologic and immunophenotypic features between T-cell lymphoma and reactive infiltrates, T-cell lymphoma may not be recognized unless studies for T-cell receptor gene rearrangements are performed for CNS lesions composed of a polymorphous but predominantly T-cell infiltrate.
  • [MeSH-major] Brain Diseases / pathology. Central Nervous System Neoplasms / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Immunohistochemistry. In Situ Hybridization. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18196250.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Uphoff CC, Denkmann SA, Steube KG, Drexler HG: Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines. J Biomed Biotechnol; 2010;2010:904767
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
  • The high prevalence of contaminated cell cultures suggests that viral contaminations might be distributed among cultures.
  • We investigated more than 460 primate cell lines for Epstein-Barr (EBV), hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus type 1 (HIV-1), human T-cell leukemia/lymphoma virus I and II (HTLV-I/-II), and squirrel monkey retrovirus (SMRV) infections for risk assessment.
  • None of the cell lines were infected with HCV, HIV-1, or HTLV-I/-II.
  • However, one cell line displayed reverse transcriptase activity.
  • Thirty-nine cell lines harbored EBV DNA sequences.
  • Studies on the lytic phase of EBV revealed that five cell lines produce EBV particles and six further cell lines produced EBV upon stimulation.
  • One cell line contained an integrated HBV genome fragment but showed no virus production.
  • Six cell lines were SMRV-infected.
  • Newly established cell lines should be tested for EBV infections to detect B-lymphoblastoid cell lines (B-LCL).
  • B-LCLs established with EBV from cell line B95-8 should be tested for SMRV infections.
  • [MeSH-major] Primates / virology. Viruses / genetics. Viruses / isolation & purification
  • [MeSH-minor] Animals. Blotting, Southern. Cell Line. DNA, Circular / analysis. HIV-1 / genetics. HIV-1 / isolation & purification. Hepacivirus / genetics. Hepacivirus / isolation & purification. Hepatitis B virus / genetics. Hepatitis B virus / isolation & purification. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / isolation & purification. Human T-lymphotropic virus 2 / genetics. Human T-lymphotropic virus 2 / isolation & purification. Humans. In Situ Hybridization, Fluorescence. Polymerase Chain Reaction. Retroviruses, Simian / genetics. Retroviruses, Simian / isolation & purification. Saimiri / virology. Viral Proteins / analysis

  • Genetic Alliance. consumer health - HIV.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 1992 Apr;4(3):205-10 [1382560.001]
  • [Cites] ALTEX. 2005;22(2):103-9 [15953965.001]
  • [Cites] J Virol Methods. 1992 Sep;39(3):259-68 [1430070.001]
  • [Cites] J Virol Methods. 1992 Dec 1;40(3):347-56 [1282132.001]
  • [Cites] Gastroenterology. 1993 Nov;105(5):1529-33 [8224658.001]
  • [Cites] Leukemia. 1994 Apr;8(4):652-8 [8152260.001]
  • [Cites] Leukemia. 1994 Aug;8(8):1385-91 [8057678.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1510-26 [8090031.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] J Hepatol. 1998 Mar;28(3):396-403 [9551676.001]
  • [Cites] DNA Cell Biol. 1998 May;17(5):415-25 [9628585.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1806-9 [9823957.001]
  • [Cites] Eur J Haematol. 1999 Jan;62(1):1-18 [9918306.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Oct 14;264(1):33-6 [10527836.001]
  • [Cites] J Hepatol. 1999 Nov;31(5):967-8 [10580600.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(14):1878-85 [10711230.001]
  • [Cites] Leuk Res. 2002 Apr;26(4):329-33 [11839374.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2002 Feb;38(2):79-85 [11928999.001]
  • [Cites] J Virol. 2002 Jun;76(11):5612-26 [11991990.001]
  • [Cites] Haemophilia. 2002 May;8(3):236-43 [12010417.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):567-74 [15160920.001]
  • [Cites] Nature. 1973 Mar 2;242(5392):44-7 [4348458.001]
  • [Cites] Int J Cancer. 1974 Mar 15;13(3):363-76 [4362611.001]
  • [Cites] Neoplasma. 1974;21(6):619-27 [4141066.001]
  • [Cites] J Virol Methods. 2006 Sep;136(1-2):193-9 [16806502.001]
  • [Cites] Adv Cancer Res. 2007;97:81-109 [17419942.001]
  • [Cites] Beitr Pathol. 1975 May;155(1):72-8 [168861.001]
  • [Cites] Science. 1977 Jan 21;195(4275):289-92 [63993.001]
  • [Cites] Virology. 1980 Mar;101(2):553-7 [6244705.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Int J Cancer. 1982 Jul 15;30(1):93-9 [6288581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Apr;80(7):1987-91 [6300885.001]
  • [Cites] J Virol. 1984 Apr;50(1):248-54 [6321792.001]
  • [Cites] Gene. 1984 Mar;27(3):279-88 [6329907.001]
  • [Cites] Cell Mol Biol. 1986;32(3):343-50 [3017561.001]
  • [Cites] Int J Cancer. 1987 Jan 15;39(1):89-93 [3098690.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Feb;84(4):1005-9 [3029758.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Mar;84(5):1332-6 [3029778.001]
  • [Cites] Eur J Biochem. 1987 Jun 1;165(2):393-401 [2439332.001]
  • [Cites] Blood. 1987 Nov;70(5):1665-72 [3478106.001]
  • [Cites] Clin Exp Immunol. 1988 Jul;73(1):23-8 [3262465.001]
  • [Cites] J Infect Dis. 1988 Dec;158(6):1193-7 [3198935.001]
  • [Cites] Virology. 1988 Dec;167(2):468-76 [3201749.001]
  • [Cites] J Exp Med. 1989 Jun 1;169(6):2191-8 [2543732.001]
  • [Cites] J Virol. 1990 Mar;64(3):1143-55 [2154599.001]
  • [Cites] Leuk Res. 1990;14(4):381-7 [2159091.001]
  • [Cites] J Med Virol. 1990 Apr;30(4):266-71 [2164560.001]
  • [Cites] Leukemia. 1991 Mar;5(3):221-4 [1849602.001]
  • [Cites] Leukemia. 1991 May;5(5):399-407 [1851909.001]
  • [Cites] Braz J Med Biol Res. 2004 Nov;37(11):1707-12 [15517087.001]
  • [Cites] Int J Cancer. 1992 Sep 30;52(3):451-4 [1339415.001]
  • (PMID = 20454443.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Circular; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2861168
  •  go-up   go-down


57. Halfdanarson TR, Rubio-Tapia A, Ristow KM, Habermann TM, Murray JA, Inwards DJ: Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma. Clin Gastroenterol Hepatol; 2010 Dec;8(12):1042-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma.
  • BACKGROUND & AIMS: Celiac disease (CD) is associated with an increased risk of lymphoma.
  • However, relatively few studies have assessed the outcome of patients diagnosed with both CD and lymphoma.
  • We evaluated the temporal association between lymphoma and CD, along with clinical presentation, response to therapy, and prognosis.
  • METHODS: Patients diagnosed with both CD and lymphoma were identified retrospectively in a tertiary referral center.
  • Clinical characteristics and survival were analyzed.
  • RESULTS: Sixty-three patients (36 men) were identified who had been diagnosed with lymphoma and CD.
  • Thirty-six (57%) were diagnosed with CD before they were diagnosed with lymphoma.
  • The most common histologic entity was diffuse, large, B-cell lymphoma, which affected 18 (29%) patients.
  • Complete information for staging was available in 59 patients; 24 (38%) had stage IV disease.
  • Survival of patients with T-cell lymphoma was shorter than for all other lymphomas (119.4 vs 22.8 mo; P = .02).
  • CONCLUSIONS: CD is associated with B- and T-cell lymphomas.
  • Patients with B-cell lymphomas had a better prognosis than those with T-cell lymphoma.
  • Therapy is unsatisfactory for enteropathy-type T-cell lymphoma.

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] Lancet. 2000 Jul 15;356(9225):203-8 [10963198.001]
  • [Cites] Am J Gastroenterol. 2010 Jun;105(6):1412-20 [20145607.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1635-45 [12414511.001]
  • [Cites] Arch Intern Med. 2003 Feb 10;163(3):286-92 [12578508.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2517-24 [12815137.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):40-6 [12851869.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):730-45 [12949719.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Jan;1(1):19-27 [15017513.001]
  • [Cites] Lancet. 1978 Jan 14;1(8055):67-70 [74567.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):795-803 [10673521.001]
  • [Cites] Digestion. 2000;62(1):60-5 [10899727.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 Jan 1;286(6358):16-8 [6401441.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Gut. 1989 Mar;30(3):333-8 [2707633.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] BMJ. 1994 Jan 1;308(6920):13-5 [8298344.001]
  • [Cites] Gut. 1994 Sep;35(9):1215-8 [7959226.001]
  • [Cites] J Clin Gastroenterol. 1995 Sep;21(2):123-9 [8583077.001]
  • [Cites] Gut. 1996 Apr;38(4):528-30 [8707082.001]
  • [Cites] Gastroenterology. 1998 Mar;114(3):471-81 [9496937.001]
  • [Cites] Gut. 2005 Jan;54(1):54-9 [15591504.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4 Suppl 1):S79-86 [15825131.001]
  • [Cites] CA Cancer J Clin. 2005 Nov-Dec;55(6):368-76 [16282281.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Feb;18(2):187-94 [16394801.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):315-9 [16527694.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Nov;4(11):1320-1 [17110301.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1981-2002 [17087937.001]
  • [Cites] Blood. 2007 Jan 15;109(2):412-21 [16973955.001]
  • [Cites] Br J Haematol. 2007 Jan;136(1):111-3 [17116129.001]
  • [Cites] Br J Haematol. 2007 Apr;137(2):170; author reply 171 [17391498.001]
  • [Cites] Aliment Pharmacol Ther. 2007 May 15;25(10):1237-45 [17451570.001]
  • [Cites] Gastroenterology. 2007 May;132(5):1902-11 [17484883.001]
  • [Cites] Dig Liver Dis. 2007 Jul;39(7):634-41 [17531561.001]
  • [Cites] Gut. 2007 Oct;56(10):1373-8 [17470479.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1731-43 [17960014.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Dec;5(12):1399-405, 1405.e1-2 [17967566.001]
  • [Cites] Scand J Gastroenterol. 2008;43(11):1322-8 [18618372.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 Jan;21(1):66-70 [19011576.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):91-8 [18950631.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):99-107; quiz 352-3 [18996383.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):81-90 [19014942.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):88-93 [19362553.001]
  • [Cites] Gut. 2010 Apr;59(4):547-57 [20332526.001]
  • [Cites] Blood. 2010 May 6;115(18):3664-70 [20197551.001]
  • [Cites] JAMA. 2002 Mar 20;287(11):1413-9 [11903028.001]
  • (PMID = 20851210.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK057892; United States / NIAID NIH HHS / AI / T32 AI007047; United States / NIDDK NIH HHS / DK / DK-57892; United States / NIAID NIH HHS / AI / T32 AI-07047
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS237618; NLM/ PMC3594736
  •  go-up   go-down


58. Persico M, Capasso M, Persico E, Masarone M, Renzo Ad, Spano D, Bruno S, Iolascon A: Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J Hepatol; 2006 Dec;45(6):779-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection.
  • BACKGROUND/AIMS: In this study, we determined the genotypic and allelic frequencies of the Interleukin (IL)-10(-1082G/A) IL-10(-592A/C), and IL-10(-819C/T) polymorphisms, and their association with the risk to develop B cell Non Hodgkin Lymphoma (NHL) in hepatitis virus C (HCV) carriers.
  • RESULTS: Genetic polymorphisms in the IL-10 gene promoter were studied in 250 consecutive patients with B-cell NHL with no clinical and/or laboratory findings of cryoglobulinemia, 142 NHL/HCV- and 108 NHL/HCV+ with chronic hepatitis (CH), 120 consecutive subjects with HCV-related CH, and 110 age, sex-matched healthy blood donors.
  • The frequency of the IL-10(-1082GG) genotype vs remaining genotypes (IL-10(-1082GA/AA)) was higher in NHL/HCV+ patients than HCV-related CH patients (P=0.0002, OR=2.89, CI: 1.62-5.15) and in NHL/HCV+ than NHL/HCV- patients (P=0.0001, OR=2.99, CI: 1.72-5.19).
  • Finally, we confirmed that IL-10(-1082GG) genotype is associated with higher IL-10 production compared to AA homozygous (P=0.037).
  • CONCLUSIONS: The high IL-10 production, due to IL-10(-1082GG) genotype, influences the clinical expression of the HCV infection by increasing susceptibility to develop NHL and might contribute to the indolent form of the disease.
  • [MeSH-minor] Adult. Aged. Alleles. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / etiology. Lymphoma, B-Cell / genetics. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. RNA, Viral / analysis. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17049666.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral; 130068-27-8 / Interleukin-10; 9007-49-2 / DNA
  •  go-up   go-down


59. Dögel D, Beuing O, Koenigsmann M, Diete S: [Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports]. Fortschr Neurol Psychiatr; 2008 Jan;76(1):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports].
  • Paraneoplastic limbic encephalitis (PLE) is a rare disease that is probably caused by an immunological reaction against CNS-structures.
  • Besides treatment of the underlying neoplastic disease, there is no generally applicable evidence-based treatment.
  • PLE is most frequently associated with certain carcinomas, but its occurrence with Hodgkin lymphoma has also been recognized.
  • Association with non-Hodgkin lymphoma has only been occasionally reported in single cases.
  • We report two additional patients, in whom malignant non-Hodgkin lymphomas of the B- and T-cell lines were detected.
  • Treatment with corticosteroids in one and chemotherapy in the other case were associated with clinical improvement.
  • [MeSH-major] Limbic Encephalitis / etiology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Electroencephalography. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Limbic encephalitis.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18189222.001).
  • [ISSN] 0720-4299
  • [Journal-full-title] Fortschritte der Neurologie-Psychiatrie
  • [ISO-abbreviation] Fortschr Neurol Psychiatr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


60. Hara S, Yokote T, Oka S, Akioka T, Kobayashi K, Hirata Y, Miyoshi T, Tsuji M, Hanafusa T: Endophthalmitis due to Trichosporon beigelii in acute leukemia. Int J Hematol; 2007 Jun;85(5):415-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endophthalmitis due to Trichosporon beigelii in acute leukemia.
  • The administration of AMPH-B is likely to be more effective in treating endophthalmitis due to trichosporonosis when the disease is at an early stage.
  • [MeSH-major] Endophthalmitis / complications. Endophthalmitis / microbiology. Leukemia, Myeloid / complications. Mycoses / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Trichosporon
  • [MeSH-minor] Acute Disease. Adult. Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Drug Resistance, Fungal. Female. Fluconazole / administration & dosage. Flucytosine / administration & dosage. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rocz Panstw Zakl Hig. 1994;45(4):337-46 [7792523.001]
  • [Cites] Medicine (Baltimore). 1986 Jul;65(4):268-79 [3523114.001]
  • [Cites] Cancer. 1975 Sep;36(3):1106-10 [52400.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1210-4 [2045861.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jan;44(1):57-62 [10602723.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):764-71 [10072411.001]
  • [Cites] Curr Top Med Mycol. 1993;5:79-113 [8242806.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Jun;46(6):1857-69 [12019101.001]
  • [Cites] Ophthalmology. 1982 Feb;89(2):152-6 [6951137.001]
  • [Cites] Infect Dis Clin North Am. 1989 Mar;3(1):43-52 [2647833.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2107-11 [6945903.001]
  • [Cites] Retina. 2003 Jun;23(3):404-5 [12824845.001]
  • [Cites] Med Mycol. 2000 Feb;38(1):27-30 [10746224.001]
  • [Cites] Cancer. 1980 Jan 15;45(2):367-71 [6927961.001]
  • [Cites] Br J Ophthalmol. 1974 Jun;58(6):591-4 [4425639.001]
  • [Cites] Clin Infect Dis. 1992 Mar;14 Suppl 1:S161-9 [1314105.001]
  • [Cites] Clin Microbiol Infect. 2001;7 Suppl 2:8-24 [11525222.001]
  • [Cites] Rev Infect Dis. 1989 May-Jun;11(3):369-78 [2749101.001]
  • [Cites] Scand J Infect Dis. 1978;10(3):225-6 [715385.001]
  • [Cites] Am J Ophthalmol. 2005 Jan;139(1):135-40 [15652837.001]
  • [Cites] J Med Microbiol. 1970 Feb;3(1):191-3 [5448879.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Chemotherapy. 1998 Jan-Feb;44(1):55-62 [9444410.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1997 Jul;35(7):553-60 [9263735.001]
  • [Cites] J Clin Lab Anal. 1995;9(5):334-9 [8531015.001]
  • [Cites] Clin Infect Dis. 1992 Nov;15(5):781-7 [1445976.001]
  • [Cites] Clin Infect Dis. 2003 Mar 1;36(5):630-7 [12594645.001]
  • [Cites] J Clin Microbiol. 1998 Oct;36(10 ):2950-6 [9738049.001]
  • [Cites] Mycoses. 1994 Jan-Feb;37(1-2):3-10 [7935589.001]
  • (PMID = 17562617.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole; D83282DT06 / Flucytosine
  •  go-up   go-down


61. Peloponese JM, Yeung ML, Jeang KT: Modulation of nuclear factor-kappaB by human T cell leukemia virus type 1 Tax protein: implications for oncogenesis and inflammation. Immunol Res; 2006;34(1):1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of nuclear factor-kappaB by human T cell leukemia virus type 1 Tax protein: implications for oncogenesis and inflammation.
  • Human T cell leukemia virus type 1 (HTLV-1) is the causative agent of a fatal malignancy known as adult T cell leukemia (ATL) and an inflammatory disease named tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM).
  • HTLV-1 encodes an oncoprotein, Tax, which plays a significant role in the initiation of cellular transformation and the elicitation of the host's inflammatory responses.
  • [MeSH-major] Cell Transformation, Neoplastic / immunology. Gene Products, tax / immunology. HTLV-I Infections / immunology. Human T-lymphotropic virus 1 / immunology. Inflammation / immunology. NF-kappa B / immunology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720895.001).
  • [ISSN] 0257-277X
  • [Journal-full-title] Immunologic research
  • [ISO-abbreviation] Immunol. Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / NF-kappa B
  • [Number-of-references] 102
  •  go-up   go-down


62. Miyano-Kurosaki N, Kira J, Barnor JS, Maeda N, Misawa N, Kawano Y, Tanaka Y, Yamamoto N, Koyanagi Y: Autonomous proliferation of HTLV-CD4+ T cell clones derived from human T cell leukemia virus type I (HTLV-I)-associated myelopathy patients. Microbiol Immunol; 2007;51(2):235-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autonomous proliferation of HTLV-CD4+ T cell clones derived from human T cell leukemia virus type I (HTLV-I)-associated myelopathy patients.
  • That HTLV-I infects CD4(+) T cells and enhances their cell growth has been shown as successful long-term in vitro proliferation in the presence of IL-2.
  • It is known that T cells isolated from HAM patients possess strong ability for cell proliferation in vitro and mRNA of various cytokines are abundantly expressed in CNS tissues of HAM patients.
  • In this study, we examined the relationship between cell proliferation and ability of in vitro cytokine production of CD4(+) T cell clones isolated from HAM patients.
  • We started a culture from a single cell to isolate cell clones immediately after drawing blood from the patients using limiting dilution method, which could allow the cell to avoid in vitro HTLV-I infection after initiation of culture.
  • Many cell clones were obtained and the rate of proliferation efficiency from a single cell was as high as 80%, especially in the 4 weeks' culture cells from HAM patients.
  • Our results indicate that the ability of cell proliferation in HAM patients is not restricted in HTLV-I-infected T cells.
  • HTLV-Iuninfected CD4(+) T cells, mainly Th0 cells, also have a strong ability to respond to IL-2-stimulation, showing that unusual immune activation on T cells has been observed in HAM patients.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / virology. Human T-lymphotropic virus 1 / immunology. Paraparesis, Tropical Spastic / immunology
  • [MeSH-minor] Adult. Aged. Clone Cells. Cytokines / genetics. Cytokines / immunology. DNA, Viral / chemistry. DNA, Viral / genetics. Female. Humans. Lymphocyte Activation. Male. Middle Aged. Polymerase Chain Reaction. Receptors, Antigen, T-Cell / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17310092.001).
  • [ISSN] 0385-5600
  • [Journal-full-title] Microbiology and immunology
  • [ISO-abbreviation] Microbiol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA, Viral; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


63. Olsen M, Madsen HO, Hjalgrim H, Gregers J, Rostgaard K, Schmiegelow K: Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood. J Pediatr Hematol Oncol; 2006 Nov;28(11):734-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood.
  • The TEL-AML1 translocation, t(12;21)(p13;q22), is one of the most frequent genetic aberrations in childhood B-cell precursor acute lymphoblastic leukemia (ALL), where it occurs in 25% of all cases.
  • In contrast, the translocation is seen in only 3% of adult ALL cases.
  • Evidence suggests that the TEL-AML1 translocation occurs in utero in 1% of all newborn children at cell levels of 10 to 10.
  • In this study, we explore the prevalence of TEL-AML1-positive cells in 2 cohorts of healthy blood donors by real-time and nested reverse transcription-polymerase chain reaction.
  • Overall, TEL-AML1-positive cells were demonstrated in 10 of 2005 healthy donors, that is, a prevalence of 0.5% (95% confidence interval, 0.2-0.3%).
  • The level of TEL-AML1-positive cells was estimated to 10 to 10.
  • The observed prevalence of TEL-AML1-positive cells in healthy adults is of the same order of magnitude as the prevalence reported in healthy newborns, but the observed cell level of 10 to 10 is much lower.
  • These data indicates that prenatal TEL-AML1 subclones does not persist throughout adult life at cell levels of 10 to 10.
  • The findings are compatible with the risk of t(12;21)(p13;q22) ALL correlating with the total number of TEL-AML1-positive cells in peripheral blood in both childhood and adulthood.
  • [MeSH-major] Burkitt Lymphoma / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Oncogene Proteins, Fusion / genetics. Preleukemia / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Blood Donors. Child. Female. Humans. Male. Middle Aged. Nucleic Acid Hybridization / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114960.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


64. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, Muus P, Marmont F, Marie JP, Labar B, Thomas X, Di Raimondo F, Willemze R, Liso V, Ferrara F, Baila L, Fazi P, Zittoun R, Amadori S, de Witte T: Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol; 2009 Nov 10;27(32):5397-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
  • PURPOSE: To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in adult patients with newly diagnosed acute myeloid leukemia (AML).
  • After achieving complete remission (CR), patients were assigned to undergo either allogeneic or autologous stem-cell transplantation (SCT), depending on the availability of a sibling donor.
  • However, the disease-free survival (DFS) and survival from CR were significantly shorter in the daunorubicin arm: the 5-year DFS was 29% versus 37% and 37% in mitoxantrone and idarubicin, respectively.
  • CONCLUSION: In adult patients with AML who do not receive an allogeneic SCT, the use of mitoxantrone or idarubicin instead of daunorubicin enhances the long-term efficacy of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Mitoxantrone / administration & dosage. Remission Induction. Survival Analysis. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2001;40(2-3):231-52 [11441935.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]
  • [Cites] Leukemia. 2003 Jan;17(1):60-7 [12529661.001]
  • [Cites] Blood. 2004 Jan 15;103(2):479-85 [14512295.001]
  • [Cites] Blood. 1982 Aug;60(2):454-62 [6953986.001]
  • [Cites] Cancer Chemother Pharmacol. 1982;8(2):157-62 [7105379.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Blood. 1990 Jan 1;75(1):27-32 [2403818.001]
  • [Cites] Leukemia. 1990 Mar;4(3):177-83 [2179638.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1666-74 [2015395.001]
  • [Cites] Br J Haematol. 1991 Jul;78(3):325-9 [1651754.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(6):480-3 [1934252.001]
  • [Cites] Blood. 1992 Jan 15;79(2):313-9 [1730080.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3267-73 [1596567.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1103-11 [1607916.001]
  • [Cites] Ann Hematol. 1994 Jul;69(1):11-5 [8061102.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] Lancet. 1998 Mar 7;351(9104):700-8 [9504514.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Leuk Lymphoma. 1998 Jan;28(3-4):315-27 [9517503.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):100-9 [9792296.001]
  • [ErratumIn] J Clin Oncol. 2010 Mar 10;28(8):1438
  • (PMID = 19826132.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 2U10-CA11488-36; United States / NCI NIH HHS / CA / CA11488-23
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ PMC2773224
  •  go-up   go-down


65. Rollinson S, Kesby H, Morgan GJ: Haplotypic variation in MRE11, RAD50 and NBS1 and risk of non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Dec;47(12):2567-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haplotypic variation in MRE11, RAD50 and NBS1 and risk of non-Hodgkin's lymphoma.
  • The MRE11-RAD50-NBS1 tri-complex is involved in the cellular response to DNA double strand breaks, detecting DNA damage, activating cell cycle checkpoints and apoptosis.
  • Defects in members of the tri-complex are linked to increased chromosomal instability and in lymphoma predisposition.
  • Using genotyping data from six intronic or gene flanking variants in MRE11, five in NBS1 and six in RAD50 in 461 non-Hodgkin's lymphoma cases and 461 age, sex matched controls, Phase 2.1 was used to impute haplotypes for each of these genes.
  • A protective effect against follicular lymphoma was seen for the MRE11 rs601341 variant, the homozygous T allele being associated with an odds ratio (OR) of 0.50, 95% confidence interval (95% CI) 0.26 - 0.97, while a protective effect was seen for the MRE11 haplotype GCTCA (OR 0.72, 95% CI 0.53 - 0.97) for diffuse large B-cell lymphoma.
  • While reproduction of this data in other datasets is indicated, the results are indicative for a role for MRE11 in non-Hodgkin's lymphoma.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics. Haplotypes. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. DNA Repair. Female. Genotype. Humans. Linkage Disequilibrium. Male. Middle Aged. Risk

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169801.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / MRE11A protein, human; 0 / NBN protein, human; 0 / Nuclear Proteins; 0 / Rad50 protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


66. Cheadle EJ, Gilham DE, Thistlethwaite FC, Radford JA, Hawkins RE: Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol; 2005 May;129(3):322-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.
  • However, tumours can avoid T cell-mediated attack through multiple mechanisms including downregulation of major histocompatability complex (MHC).
  • Consequently, engineering T cells to target intact protein antigen directly, thus bypassing the need for MHC presentation, can facilitate T cell targeting of tumour cells.
  • Peripheral blood lymphocytes from nine of nine patients with non-Hodgkin lymphoma (NHL) were successfully gene-modified to express a receptor consisting of a CD19 single chain variable fragment (scFv) fused to the T cell CD3zeta signalling molecule.
  • These T cells were functionally active against the CD19(+) Raji Burkitt's lymphoma cell line.
  • These results demonstrate that patients with CD19(+) NHL would be suitable candidates for this form of therapy in the setting of a phase I clinical trial.
  • [MeSH-major] Antigens, CD19 / analysis. Lymphocyte Transfusion / methods. Lymphoma, Non-Hodgkin / pathology. T-Lymphocyte Subsets / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD3 / immunology. Biopsy. Cytotoxicity, Immunologic. Female. Genetic Vectors. Humans. Immunotherapy, Adoptive / methods. Interferon-gamma / biosynthesis. Lymphocyte Activation. Male. Middle Aged. Retroviridae / genetics. Transduction, Genetic. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842655.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD3; 0 / CD3 antigen, zeta chain; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


67. Salem HK, Thiemermann C: Mesenchymal stromal cells: current understanding and clinical status. Stem Cells; 2010 Mar 31;28(3):585-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal stromal cells: current understanding and clinical status.
  • Multipotent mesenchymal stromal cells (MSCs) represent a rare heterogeneous subset of pluripotent stromal cells that can be isolated from many different adult tissues that exhibit the potential to give rise to cells of diverse lineages.
  • In addition, MSCs possess remarkable immunosuppressive properties, suppressing T-cell, NK cell functions, and also modulating dentritic cell activities.
  • Tremendous progress has been made in preclinical studies using MSCs, including the ability to use allogeneic cells, which has driven the application of MSCs toward the clinical setting.
  • This review highlights our current understanding into the biology of MSCs with particular emphasis on the cardiovascular and renal applications, and provides a brief update on the clinical status of MSC-based therapy.
  • [MeSH-major] Immune Tolerance / physiology. Mesenchymal Stem Cell Transplantation / methods. Mesenchymal Stromal Cells / immunology. Stromal Cells / immunology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Immunol. 2003 Jan;57(1):11-20 [12542793.001]
  • [Cites] Transplantation. 2003 Feb 15;75(3):389-97 [12589164.001]
  • [Cites] J Biomed Sci. 2003 Mar-Apr;10(2):228-41 [12595759.001]
  • [Cites] Biochem Soc Symp. 2002;(69):33-45 [12655772.001]
  • [Cites] J Cell Sci. 2003 May 1;116(Pt 9):1827-35 [12665563.001]
  • [Cites] Zhonghua Er Bi Yan Hou Ke Za Zhi. 2002 Apr;37(2):137-9 [12768728.001]
  • [Cites] Cardiovasc Res. 2003 Jul 1;59(1):132-42 [12829184.001]
  • [Cites] Transplantation. 2003 Oct 27;76(8):1208-13 [14578755.001]
  • [Cites] J Gene Med. 2003 Dec;5(12):1028-38 [14661178.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jan;190(1):239-45 [14749666.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1662-8 [14592819.001]
  • [Cites] Circ Res. 2004 Mar 19;94(5):678-85 [14739163.001]
  • [Cites] Blood. 2004 May 1;103(9):3313-9 [14715641.001]
  • [Cites] Nat Rev Immunol. 2004 Jun;4(6):432-44 [15173832.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4619-21 [15001472.001]
  • [Cites] Stem Cells Dev. 2004 Jun;13(3):263-71 [15186722.001]
  • [Cites] J Am Soc Nephrol. 2004 Jul;15(7):1794-804 [15213267.001]
  • [Cites] Am J Cardiol. 2004 Jul 1;94(1):92-5 [15219514.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Jul;229(7):623-31 [15229356.001]
  • [Cites] Lancet. 2004 Jul 10-16;364(9429):141-8 [15246726.001]
  • [Cites] Biorheology. 2004;41(3-4):469-76 [15299278.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2643-5 [15251986.001]
  • [Cites] Chin Med J (Engl). 2004 Oct;117(10):1443-8 [15498362.001]
  • [Cites] Transplantation. 1968 Mar;6(2):230-47 [5654088.001]
  • [Cites] Am J Cardiol. 1991 Nov 18;68(14):1D-6D [1836091.001]
  • [Cites] Ann N Y Acad Sci. 1995 Mar 27;752:72-9 [7755297.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 23;92(11):4857-61 [7761413.001]
  • [Cites] Muscle Nerve. 1995 Dec;18(12):1417-26 [7477065.001]
  • [Cites] J Biol Chem. 1995 Dec 8;270(49):29439-46 [7493982.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):165-75 [8546203.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):86-107 [8569201.001]
  • [Cites] Exp Cell Res. 1996 Aug 1;226(2):316-27 [8806435.001]
  • [Cites] Blood. 1996 Nov 1;88(9):3259-87 [8896391.001]
  • [Cites] Science. 1997 Apr 4;276(5309):71-4 [9082988.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8801-5 [9671759.001]
  • [Cites] Ageing Res Rev. 2006 Feb;5(1):91-116 [16310414.001]
  • [Cites] Stem Cells. 2006 Jan;24(1):74-85 [16099998.001]
  • [Cites] Stem Cells. 2006 Feb;24(2):386-98 [16123384.001]
  • [Cites] Cardiovasc Revasc Med. 2006 Jan-Mar;7(1):19-24 [16513519.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2570-7 [16293599.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):1030-41 [16253981.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):1095-103 [16282438.001]
  • [Cites] Stem Cells. 2006 May;24(5):1254-64 [16410389.001]
  • [Cites] J Am Soc Nephrol. 2006 Jun;17(6):1503-20 [16707563.001]
  • [Cites] J Cell Sci. 2006 Jun 1;119(Pt 11):2204-13 [16684817.001]
  • [Cites] J Am Soc Nephrol. 2006 Aug;17(8):2202-12 [16790513.001]
  • [Cites] Int J Cardiol. 2006 Aug 10;111(2):231-9 [16246440.001]
  • [Cites] Stem Cells. 2006 Oct;24(10):2202-8 [16778152.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3938-44 [16896152.001]
  • [Cites] Mol Ther. 2006 Dec;14(6):840-50 [16965940.001]
  • [Cites] Stem Cells. 2006 Dec;24(12):2810-6 [16931770.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3711-27 [17026998.001]
  • [Cites] Blood. 2007 Jan 1;109(1):228-34 [16985180.001]
  • [Cites] Stem Cells. 2007 Jan;25(1):69-77 [16973831.001]
  • [Cites] J Interferon Cytokine Res. 2007 Jan;27(1):53-64 [17266444.001]
  • [Cites] Clin Immunol. 2007 Apr;123(1):7-13 [17064966.001]
  • [Cites] Biochem Biophys Res Commun. 2007 May 11;356(3):780-4 [17382293.001]
  • [Cites] J Cell Biochem. 2007 May 1;101(1):135-46 [17295203.001]
  • [Cites] Blood. 2007 May 1;109(9):4055-63 [17197427.001]
  • [Cites] Haematologica. 2007 Apr;92(4):440-9 [17488654.001]
  • [Cites] Arch Intern Med. 2007 May 28;167(10):989-97 [17533201.001]
  • [Cites] Stem Cells. 2007 Jul;25(7):1761-8 [17395769.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1733-8 [17541394.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1531-44 [16236607.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1106:262-71 [17395729.001]
  • [Cites] Mol Biol Cell. 2007 Aug;18(8):2873-82 [17507648.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1362-9 [17483296.001]
  • [Cites] Nat Rev Immunol. 2007 Sep;7(9):678-89 [17717539.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2363-70 [17540857.001]
  • [Cites] Stem Cells. 2007 Nov;25(11):2739-49 [17656645.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3289-96 [10828007.001]
  • [Cites] J Clin Invest. 2000 Jun;105(12):1663-8 [10862779.001]
  • [Cites] Exp Hematol. 2000 Aug;28(8):875-84 [10989188.001]
  • [Cites] J Clin Invest. 2000 Dec;106(11):1331-9 [11104786.001]
  • [Cites] N Engl J Med. 2001 Jun 7;344(23):1750-7 [11396441.001]
  • [Cites] Ann N Y Acad Sci. 2001 Jun;938:83-95 [11458529.001]
  • [Cites] Stem Cells. 2001;19(6):477-82 [11713338.001]
  • [Cites] J Am Soc Nephrol. 2001 Dec;12(12):2625-35 [11729231.001]
  • [Cites] J Clin Invest. 2002 Feb;109(3):337-46 [11827993.001]
  • [Cites] Ann Thorac Surg. 2002 Jun;73(6):1919-25; discussion 1926 [12078791.001]
  • [Cites] J Exp Med. 2002 Aug 19;196(4):459-68 [12186838.001]
  • [Cites] Heart. 2002 Oct;88 Suppl 2:ii15-22 [12213795.001]
  • [Cites] Ann Thorac Surg. 2002 Oct;74(4):1154-9; discussion 1159-60 [12400761.001]
  • [Cites] J Clin Invest. 1999 Mar;103(5):697-705 [10074487.001]
  • [Cites] Science. 1999 Apr 2;284(5411):143-7 [10102814.001]
  • [Cites] J Exp Med. 1999 May 3;189(9):1363-72 [10224276.001]
  • [Cites] J Cell Physiol. 1999 Oct;181(1):67-73 [10457354.001]
  • [Cites] Immunol Today. 1999 Oct;20(10):469-73 [10500295.001]
  • [Cites] Int J Mol Med. 2004 Dec;14(6):1035-41 [15547670.001]
  • [Cites] Circulation. 2004 Nov 23;110(21):3300-5 [15533866.001]
  • [Cites] Stem Cells. 2005;23(1):44-54 [15625121.001]
  • [Cites] Lancet. 2005 Jan 29-Feb 4;365(9457):417-30 [15680458.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1815-22 [15494428.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2214-9 [15514012.001]
  • [Cites] J Cell Biochem. 2005 Mar 1;94(4):645-55 [15547939.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3035-9 [15833829.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 May;11(5):389-98 [15846293.001]
  • [Cites] Eur J Immunol. 2005 May;35(5):1482-90 [15827960.001]
  • [Cites] Blood. 2005 May 15;105(10):4120-6 [15692068.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Jul;289(1):F31-42 [15713913.001]
  • [Cites] Blood. 2005 Jul 15;106(2):419-27 [15784733.001]
  • [Cites] Catheter Cardiovasc Interv. 2005 Jul;65(3):321-9 [15954106.001]
  • [Cites] Circulation. 2005 Jul 12;112(2):214-23 [15998673.001]
  • [Cites] Circulation. 2005 Jul 26;112(4):521-6 [16027258.001]
  • [Cites] Circulation. 2005 Aug 23;112(8):1128-35 [16103243.001]
  • [Cites] Blood. 2005 Sep 15;106(6):1901-10 [15890683.001]
  • [Cites] Kidney Int. 2005 Oct;68(4):1613-7 [16164638.001]
  • [Cites] Cytotherapy. 2005;7(5):393-5 [16236628.001]
  • [Cites] Mol Ther. 2006 Jan;13(1):49-58 [16216560.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18111-6 [16326806.001]
  • [Cites] Nat Immunol. 2005 Dec;6(12):1182-90 [16369557.001]
  • [Cites] Handb Exp Pharmacol. 2006;(174):249-82 [16370331.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] PLoS One. 2008;3(1):e1398 [18167557.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1598-608 [18209056.001]
  • [Cites] Cardiovasc Res. 2008 Feb 1;77(3):515-24 [18006453.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2581-7 [18250469.001]
  • [Cites] J Mol Cell Cardiol. 2008 Mar;44(3):486-95 [18061611.001]
  • [Cites] J Mol Cell Cardiol. 2008 Jun;44(6):1072-84 [18462748.001]
  • [Cites] Adv Cancer Res. 2008;100:133-58 [18620095.001]
  • [Cites] J Zhejiang Univ Sci B. 2008 Aug;9(8):630-7 [18763313.001]
  • [Cites] Blood. 2009 Jan 22;113(4):816-26 [18818395.001]
  • [Cites] Can J Physiol Pharmacol. 2009 Feb;87(2):143-50 [19234578.001]
  • [Cites] Transplantation. 2009 Mar 27;87(6):896-906 [19300194.001]
  • [Cites] Bone Marrow Transplant. 2009 Mar;43(6):447-54 [18955980.001]
  • [Cites] Stem Cells. 2009 Apr;27(4):961-70 [19353524.001]
  • [Cites] Cytotherapy. 2009;11(3):278-88 [19308773.001]
  • (PMID = 19967788.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 127
  • [Other-IDs] NLM/ PMC2962904
  •  go-up   go-down


68. Amit BH, Gil-Ad I, Taler M, Bar M, Zolokov A, Weizman A: Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on T cell lymphoma/leukemia (Jurkat) in vitro. Eur Neuropsychopharmacol; 2009 Oct;19(10):726-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on T cell lymphoma/leukemia (Jurkat) in vitro.
  • We evaluated such in vitro effects in malignant T cells (Jurkat), finding that exposure to high concentrations of sertraline (IC(50)=9.5 microM) or paroxetine (IC(50)=18 microM) yielded a considerable reduction in cellular viability, exceeding equimolar doses of the chemotherapeutics vincristine and cyclophosphamide (P<0.015).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Drug Interactions. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Serotonin Uptake Inhibitors / pharmacology
  • [MeSH-minor] Cell Proliferation / drug effects. Cell Survival / drug effects. Chemotherapy, Adjuvant. Doxorubicin / pharmacology. Humans. Jurkat Cells. Mitogen-Activated Protein Kinases / metabolism. Paroxetine / pharmacology. Sertraline / pharmacology. Vincristine / pharmacology

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PAROXETINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. SERTRALINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19631512.001).
  • [ISSN] 1873-7862
  • [Journal-full-title] European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
  • [ISO-abbreviation] Eur Neuropsychopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Serotonin Uptake Inhibitors; 41VRH5220H / Paroxetine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; QUC7NX6WMB / Sertraline
  •  go-up   go-down


69. Burgoyne LL, Anghelescu DL, Tamburro RF, De Armendi AJ: A pediatric patient with a mediastinal mass and pulmonary embolus. Paediatr Anaesth; 2006 Apr;16(4):487-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We suggest that pulmonary embolism should be considered in the differential diagnosis when a patient with a mediastinal mass develops perioperative hypoxaemia, cardiovascular collapse, or both.
  • [MeSH-minor] Anoxia / etiology. Cardiovascular Diseases / etiology. Cardiovascular Diseases / pathology. Child. Fatal Outcome. Humans. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / pathology. Male. Pulmonary Artery / pathology. Tomography, X-Ray Computed. Ventilation-Perfusion Ratio / physiology

  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618309.001).
  • [ISSN] 1155-5645
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


70. Watanabe T, Terui S, Itoh K, Terauchi T, Igarashi T, Usubuchi N, Nakata M, Nawano S, Sekiguchi N, Kusumoto S, Tanimoto K, Kobayashi Y, Endo K, Seriu T, Hayashi M, Tobinai K: Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. Cancer Sci; 2005 Dec;96(12):903-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.
  • We conducted a phase I study to evaluate the safety and efficacy of radioimmunotherapy with yttrium-90-ibritumomab tiuxetan (Y2B8) in Japanese patients with relapsed or refractory indolent B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / toxicity. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / adverse effects. Yttrium Radioisotopes / toxicity
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Reproducibility of Results. Tissue Distribution

  • Genetic Alliance. consumer health - Indolent B cell lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Cancer Sci 2005; 96: 903-910).
  • (PMID = 16367911.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


71. Aifantis I, Raetz E, Buonamici S: Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol; 2008 May;8(5):380-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of T-cell leukaemia and lymphoma.
  • T-cell acute lymphoblastic leukaemia (T-ALL) is induced by the transformation of T-cell progenitors and mainly occurs in children and adolescents.
  • Although treatment outcome in patients with T-ALL has improved in recent years, patients with relapsed disease continue to have a poor prognosis.
  • It is therefore important to understand the molecular pathways that control both the induction of transformation and the treatment of relapsed disease.
  • In this Review, we focus on the molecular mechanisms responsible for disease induction and maintenance.
  • We also compare the physiological progression of T-cell differentiation with T-cell transformation, highlighting the close relationship between these two processes.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18421304.001).
  • [ISSN] 1474-1741
  • [Journal-full-title] Nature reviews. Immunology
  • [ISO-abbreviation] Nat. Rev. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA105129; United States / NCI NIH HHS / CA / R01CA105129; United States / NCI NIH HHS / CA / T32 CA-09161
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Homeodomain Proteins; 0 / NF-kappa B; 0 / Receptor, Notch1; 0 / Transcription Factors; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Number-of-references] 101
  •  go-up   go-down


72. Satoh J, Nakanishi M, Koike F, Miyake S, Yamamoto T, Kawai M, Kikuchi S, Nomura K, Yokoyama K, Ota K, Kanda T, Fukazawa T, Yamamura T: Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol Dis; 2005 Apr;18(3):537-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To clarify the molecular mechanisms underlying multiple sclerosis (MS)-promoting autoimmune process, we have investigated a comprehensive gene expression profile of T cell and non-T cell fractions of peripheral blood mononuclear cells (PBMC) isolated from 72 MS patients and 22 age- and sex-matched healthy control (CN) subjects by using a cDNA microarray.
  • They included upregulation in MS of orphan nuclear receptor Nurr1 (NR4A2), receptor-interacting serine/threonine kinase 2 (RIPK2), and silencer of death domains (SODD), and downregulation in MS of TNF-related apoptosis-inducing ligand (TRAIL), B-cell CLL/lymphoma 2 (BCL2), and death-associated protein 6 (DAXX).
  • [MeSH-minor] Adult. Down-Regulation / genetics. Female. Humans. Male. Middle Aged. Up-Regulation / genetics

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755681.001).
  • [ISSN] 0969-9961
  • [Journal-full-title] Neurobiology of disease
  • [ISO-abbreviation] Neurobiol. Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T: Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood; 2009 May 14;113(20):4885-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
  • Although rituximab is a key molecular targeting drug for CD20-positive B-cell lymphomas, resistance to rituximab has recently been recognized as a considerable problem.
  • Here, we report that a CD20-negative phenotypic change after chemotherapies with rituximab occurs in a certain number of CD20-positive B-cell lymphoma patients.
  • For 5 years, 124 patients with B-cell malignancies were treated with rituximab-containing chemotherapies in Nagoya University Hospital.
  • Of those 19, 5 (26.3%; diffuse large B-cell lymphoma [DLBCL], 3 cases; DLBCL transformed from follicular lymphoma, 2 cases) indicated CD20 protein-negative transformation.
  • Quantitative reverse-transcription-polymerase chain reaction (RT-PCR) showed that CD20 mRNA expression was significantly lower in CD20-negative cells than in CD20-positive cells obtained from the same patient.
  • Interestingly, when CD20-negative cells were treated with 5-aza-2'-deoxycytidine in vitro, the expression of CD20 mRNA was stimulated within 3 days, resulting in the restoration of both cell surface expression of the CD20 protein and rituximab sensitivity.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Down-Regulation / drug effects. Epigenesis, Genetic / drug effects. Epigenesis, Genetic / physiology. Follow-Up Studies. Gene Expression Regulation, Neoplastic / drug effects. Humans. Middle Aged. Mutation. Phenotype. Prognosis. RNA, Messenger / metabolism. Rituximab. Young Adult


74. Yasuda I, Tsurumi H, Omar S, Iwashita T, Kojima Y, Yamada T, Sawada M, Takami T, Moriwaki H, Soehendra N: Endoscopic ultrasound-guided fine-needle aspiration biopsy for lymphadenopathy of unknown origin. Endoscopy; 2006 Sep;38(9):919-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND STUDY AIMS: The diagnosis of mediastinal and intra-abdominal lymphadenopathy is sometimes difficult, especially in patients who have no other primary lesions.
  • Lymphoma is one of the main causes of this condition.
  • However, diagnosing lymphoma using the EUS-FNA technique remains a diagnostic challenge, due to limitations in the amount of material sampled.
  • The aim of the present study was to evaluate the yield of EUS-FNA biopsy (EUS-FNAB) using a large-gauge needle in patients with mediastinal and intra-abdominal lymphadenopathy of unknown origin, especially in relation to subclassification of the lymphomas.
  • The diagnoses made using EUS-FNAB were lymphoma (n = 48), metastasis (n = 16), and benign/reactive (n = 40).
  • The overall accuracy of EUS-FNAB for unknown lymphadenopathy was 98 %, and it was possible to classify the lymphomas in accordance with the World Health Organization classifications in 88 % of cases.
  • CONCLUSIONS: Open thoracic surgery, laparotomy, and other invasive diagnostic procedures such as mediastinoscopy and laparoscopy can now be avoided, as EUS-FNAB is potentially a safe and accurate tool for diagnosing unknown lymphadenopathy, including lymphoma.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Endosonography. Lymphatic Diseases / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, T-Cell / diagnosis. Male. Middle Aged. Prospective Studies. Sensitivity and Specificity


75. Harting R, Venugopal P, Gregory SA, O'brien T, Bogdanova E: Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma; 2007 May;7(6):406-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
  • BACKGROUND: We evaluated the efficacy and safety of adding rituximab to nonanthracycline ESHAP (etoposide/methylprednisolone/cytarabine/cisplatin) chemotherapy for relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).
  • Thirteen patients were enrolled (median age, 56 years); all had previously treated NHL, 12 (92%) had diffuse large B-cell lymphoma, 10 (77%) had stage III/IV disease, and 2 (15%) had chemotherapy-refractory disease.
  • Among 6 patients completing all 6 cycles, 4 (67%) had a CR, 1 had a partial response, and 1 had progressive disease.
  • CONCLUSION: Rituximab plus ESHAP led to durable responses with acceptable toxicity in patients with relapsed/refractory aggressive NHL, most of whom had advanced disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / chemically induced. Antibodies, Monoclonal, Murine-Derived. Cisplatin / adverse effects. Cisplatin / therapeutic use. Creatinine / urine. Cytarabine / adverse effects. Cytarabine / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Male. Methylprednisolone / adverse effects. Methylprednisolone / therapeutic use. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Platelet Count. Prospective Studies. Rituximab. Thrombocytopenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621406.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; AYI8EX34EU / Creatinine; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


76. Dewan MZ, Uchihara JN, Terashima K, Honda M, Sata T, Ito M, Fujii N, Uozumi K, Tsukasaki K, Tomonaga M, Kubuki Y, Okayama A, Toi M, Mori N, Yamamoto N: Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood; 2006 Jan 15;107(2):716-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir.
  • Adult T-cell leukemia (ATL), an aggressive malignancy of CD4+ T cells associated with human T-cell leukemia virus type I (HTLV-I) infection, carries a very poor prognosis because of the resistance of leukemic cells to any conventional regimen, including chemotherapy.
  • We examined the effect of ritonavir, an HIV protease inhibitor, on HTLV-I-infected T-cell lines and primary ATL cells and found that it induced apoptosis and inhibited transcriptional activation of NF-kappaB in these cells.
  • Our data indicate that ritonavir has potent anti-NF-kappaB and antitumor effects and might be clinically applicable for treatment of ATL.
  • These results would provide a new concept and novel platform for new drug development of leukemia and solid cancer as well.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Cyclin D2. Cyclins / metabolism. Disease Models, Animal. Female. Human T-lymphotropic virus 1 / physiology. Humans. Inhibitor of Apoptosis Proteins. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / virology. Male. Mice. Mice, Inbred NOD. Mice, SCID. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-myc / metabolism. bcl-X Protein / metabolism

  • Genetic Alliance. consumer health - HIV.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174765.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / HIV Protease Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / MYC protein, human; 0 / Microtubule-Associated Proteins; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / bcl-X Protein; O3J8G9O825 / Ritonavir
  •  go-up   go-down


77. Yamada Y, Kamihira S: Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1553-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma.
  • Almost three decades have passed since adult T-cell leukemia-lymphoma (ATLL) was proposed as a new disease entity.
  • During this period, its causative agent, human T-cell leukemia virus type-1 (HTLV-1), was found and a crucial role of the viral product Tax in the development of ATLL was disclosed.
  • However, the long latent period after infection with HTLV-1 indicates the need for additional factors for full-blown ATLL, most of which are supposed to be provided by somatic mutations of cellular genes.
  • Recent progress in cell-cycle research has revealed that the uncontrolled and superior proliferative activity of malignant cells is mainly caused by the breakdown of cell-cycle regulation and that most malignancies carry aberrations in p16-pRB and/or p53 pathways.
  • ATLL is not an exception, despite the consistent association of HTLV-1 in primary leukemia cells, and accumulating evidence indicates that the breakdown of these pathways is indeed involved in the leukemogenesis of ATLL, especially in its later steps, which serve as the key events for promotion of indolent ATLL to aggressive ATLL.
  • [MeSH-major] Gene Silencing. Genes, Tumor Suppressor. Leukemia-Lymphoma, Adult T-Cell / etiology
  • [MeSH-minor] Disease Progression. Genes, cdc. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236609.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


78. Prochazka V, Trneny M, Pytlik R, Vasova I, Kral Z, Belada D, Kozak T, Kubackova K, Siffnerova H, Matuska M, Lysy M, Bolomska I, Petrakova K, Otavova B, Pribylova J, Svecova J, Papajik T, Hamouzova M, Petrova M, Zapletalova J, Langova K: Peripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun;151(1):103-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry.
  • BACKGROUND: Peripheral T-cell lymphoma, unspecified (PTCL-US) is one of the entities from the infrequent family of nodal mature T-cell lymphomas.
  • The clinical course is aggressive, and despite multiagent chemotherapy, the median survival is about 2 years.
  • Published data are limited to retrospective, mostly single-center studies or reviews and usually include more lymphoma subtypes.
  • AIM: To evaluate the current treatment modalities, clinical outcome and prognostic factors in unselected, new diagnosed patients with PTCL-US in the population of the central european region (Czech Republic).
  • METHOD: Czech Lymphoma Study Group is a national scientific organization which provides an on-line database registry which collects a data about almost all new diagnosed lymphoma patients since year 2000.
  • RESULTS: We analyzed 63 patients with new diagnosis of PTCL-US.
  • After a median follow-up of 19.6 months, 41% of the patients were in CR, 3.4% in PR or stable disease and 55% of the patients died.
  • Clinical stage (IV) and CR achievement were found to be independent survival predictors in a multivariate analysis.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690750.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


79. Murata K, Hayashibara T, Sugahara K, Uemura A, Yamaguchi T, Harasawa H, Hasegawa H, Tsuruda K, Okazaki T, Koji T, Miyanishi T, Yamada Y, Kamihira S: A novel alternative splicing isoform of human T-cell leukemia virus type 1 bZIP factor (HBZ-SI) targets distinct subnuclear localization. J Virol; 2006 Mar;80(5):2495-505
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel alternative splicing isoform of human T-cell leukemia virus type 1 bZIP factor (HBZ-SI) targets distinct subnuclear localization.
  • Adult T-cell leukemia (ATL) is associated with prior infection with human T-cell leukemia virus type 1 (HTLV-1); however, the mechanism by which HTLV-1 causes adult T-cell leukemia has not been fully elucidated.
  • Recently, a functional basic leucine zipper (bZIP) protein coded in the minus strand of HTLV-1 genome (HBZ) was identified.
  • We report here a novel isoform of the HTLV-1 bZIP factor (HBZ), HBZ-SI, identified by means of reverse transcription-PCR (RT-PCR) in conjunction with 5' and 3' rapid amplification of cDNA ends (RACE).
  • HBZ-SI is a 206-amino-acid-long protein and is generated by alternative splicing between part of the HBZ gene and a novel exon located in the 3' long terminal repeat of the HTLV-1 genome.
  • Duplex RT-PCR and real-time quantitative RT-PCR analyses showed that the mRNAs of these isoforms were expressed at equivalent levels in all ATL cell samples examined.
  • Nonetheless, we found by Western blotting that the HBZ-SI protein was preferentially expressed in some ATL cell lines examined.
  • A key finding was obtained from the subcellular localization analyses of these isoforms.
  • These data show the presence of a novel isoform of HBZ in ATL cells, and in addition, shed new light on the possibility that each isoform may play a unique role in distinct regions in the cell nucleus.
  • [MeSH-major] Alternative Splicing. Basic-Leucine Zipper Transcription Factors / genetics. Basic-Leucine Zipper Transcription Factors / metabolism. Cell Nucleus / metabolism. Human T-lymphotropic virus 1 / genetics. RNA Processing, Post-Transcriptional. RNA, Messenger / metabolism. RNA, Viral / metabolism. Viral Proteins / genetics. Viral Proteins / metabolism
  • [MeSH-minor] Amino Acid Sequence. Artificial Gene Fusion. Base Sequence. Biological Transport. Blotting, Western. Cell Line, Tumor. Green Fluorescent Proteins / analysis. Green Fluorescent Proteins / genetics. Humans. Microscopy, Fluorescence. Molecular Sequence Data. Protein Isoforms / chemistry. Protein Isoforms / genetics. Protein Isoforms / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Feb 15;97(4):987-93 [11159527.001]
  • [Cites] J Cell Sci. 2005 Apr 1;118(Pt 7):1355-62 [15755797.001]
  • [Cites] Virus Genes. 2001;23(2):123-35 [11724264.001]
  • [Cites] J Virol. 2002 Dec;76(24):12813-22 [12438606.001]
  • [Cites] Nutr Cancer. 2002;44(2):193-201 [12734068.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43620-7 [12937177.001]
  • [Cites] FEBS Lett. 2004 Mar 26;562(1-3):165-70 [15044019.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):43998-4004 [15308664.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Mar;78(3):1887-91 [6262827.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Crit Rev Microbiol. 1986;12(4):293-320 [3007026.001]
  • [Cites] Adv Virus Res. 1985;30:225-77 [3008524.001]
  • [Cites] Cell. 1987 Jan 30;48(2):343-50 [3026643.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5389-93 [3037548.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Sep 15;163(2):1006-13 [2476979.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57 [1751545.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):4042-6 [1315048.001]
  • [Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]
  • [Cites] Jpn J Cancer Res. 1993 Jan;84(1):4-8 [8449826.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):234-41 [7803265.001]
  • [Cites] Blood. 1995 May 15;85(10):2699-704 [7742529.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1551-60 [8781409.001]
  • [Cites] Leuk Lymphoma. 1996 May;21(5-6):443-7 [9172809.001]
  • [Cites] Int J Cancer. 1996 Sep 27;68(1):102-8 [8895548.001]
  • [Cites] J Virol. 1997 Apr;71(4):3188-96 [9060682.001]
  • [Cites] J Virol. 1998 Jan;72(1):388-95 [9420237.001]
  • [Cites] EMBO J. 1998 Mar 2;17(5):1476-86 [9482744.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3620-32 [9584203.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1001-10 [15592508.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):17920-31 [11279020.001]
  • (PMID = 16474156.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB219938
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / RNA, Viral; 0 / Viral Proteins; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ PMC1395368
  •  go-up   go-down


80. Lévy M, Copie-Bergman C, Molinier-Frenkel V, Riou A, Haioun C, Gaulard P, Delfau-Larue MH, Sobhani I, Leroy K, Delchier JC: Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up. Leuk Lymphoma; 2010 Feb;51(2):284-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up.
  • Translocation t(11;18) is a factor predictive of poor response to treatment of gastric marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT).
  • We treated 13 patients with t(11;18)-positive gastric MALT lymphoma with the combination of rituximab and chlorambucil (nine patients as first treatment and four as second line therapy).
  • At week 25, B cell monoclonality and t(11;18)-positive tumor cells were still detected in 77% and 73%, respectively.
  • However, at long term follow-up, the tumor B cell clone was present in only 30% whereas the t(11;18) was still detected in 70%.
  • The combination of rituximab - chlorambucil is highly effective in t(11;18)-positive gastric MALT lymphoma.
  • Molecular disease persists despite histological remission. t(11;18) is more sensitive than B cell clonality for the monitoring of residual molecular disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastric Mucosa / drug effects. Lymphoma, B-Cell, Marginal Zone / drug therapy. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Chlorambucil / administration & dosage. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 18 / genetics. Female. Follow-Up Studies. Helicobacter Infections / drug therapy. Helicobacter Infections / genetics. Helicobacter Infections / microbiology. Helicobacter pylori / drug effects. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / analysis. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038225.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 18D0SL7309 / Chlorambucil; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


81. Li B, Shi YK, He XH, Zou SM, Zhou SY, Dong M, Yang JL, Liu P, Xue LY: Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients. Int J Hematol; 2008 May;87(4):375-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients.
  • To investigate the clinicopathological characteristics and optimal treatment modalities of primary non-Hodgkin lymphoma (NHL) in the small and large intestine.
  • All cases were reclassified according to the World Health Organization (WHO) classification of lymphoma in 2001.
  • Fourteen patients had primary disease in the small intestine, which were all of B-cell origin with diffuse large B-cell lymphoma (DLBCL) diagnosed in 5 of 14 (35.7%) patients and mucosa-associated lymphoid tissue (MALT) lymphoma in 8 of 14 (57.1%) patients.
  • Twenty-five patients had primary colorectal lymphoma, with B-cell origin accounting for 92.0% and T-cell origin for 8.0% of these patients.
  • However, no post-operation treatment modality can improve OS or EFS for patients with MALT lymphoma.
  • B-cell lymphoma is the most common pathological type of intestinal lymphomas.
  • Chemotherapy-containing treatment modality is an effective way to improve intestinal lymphoma patients' EFS, especially for those with DLBCL subtype.
  • [MeSH-major] Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Intestine, Large / pathology. Intestine, Small / pathology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Nov;9(6):502-5 [17143795.001]
  • [Cites] Histopathology. 2003 Aug;43(2):135-43 [12877728.001]
  • [Cites] Am Surg. 1988 May;54(5):262-6 [3364860.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Cancer Causes Control. 2005 Sep;16(7):781-7 [16132788.001]
  • [Cites] Gastroenterol Jpn. 1976;11(2):141-7 [789171.001]
  • [Cites] Dig Dis Sci. 2005 Dec;50(12):2243-7 [16416168.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Am J Med. 1991 Jan;90(1):77-84 [1702581.001]
  • [Cites] Cancer. 2003 May 15;97(10):2462-73 [12733145.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Rofo. 1983 Mar;138(3):283-7 [6403420.001]
  • [Cites] Eur J Surg. 1997 Nov;163(11):803-13 [9414040.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1847-52 [15223645.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):776-82 [8471435.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):846-58 [8143991.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1208-17 [2670184.001]
  • [Cites] Br J Cancer. 1989 Aug;60(2):244-8 [2765374.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):53-8 [11249049.001]
  • [Cites] Leuk Lymphoma. 2006 Jul;47(7):1253-9 [16923554.001]
  • [Cites] Acta Oncol. 1988;27(1):51-5 [3284553.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):324-37 [10375089.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):142-4 [16750023.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1277-82 [11005497.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Med Oncol. 2006;23(2):225-35 [16720923.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):532-40 [15937928.001]
  • [Cites] Cancer. 1978 Aug;42(2):693-707 [354774.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):286-94 [10640959.001]
  • (PMID = 18409078.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Lee J, Kim WS, Park YH, Park SH, Park KW, Kang JH, Lee SS, Lee SI, Lee SH, Kim K, Jung CW, Ahn YC, Ko YH, Park K: Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer; 2005 Apr 11;92(7):1226-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal-type NK/T cell lymphoma: clinical features and treatment outcome.
  • Nasal-type NK/T cell lymphoma is an increasingly recognised disease entity of aggressive clinical behaviour.
  • The objective of this study was to investigate clinical features and treatment outcomes in patients with nasal-type NK/T cell lymphoma.
  • From January 1991 to December 2003, 26 patients diagnosed as nasal-type NK/T cell lymphoma were included in the analysis.
  • The median survival for 26 patients with nasal-type NK/T cell lymphoma was 7.4 months (95% CI, 0.1, 16.9).
  • The treatment outcome of primary anthracycline-based chemotherapy was poor: 60% CR rate in localised disease and 0% CR rate in advanced disease.
  • After a median follow-up of 24.4 months (range 3.1-99.0) in patients with localised disease who had achieved a CR (range 29.6-165.7), three patients (50.0%) developed disease recurrence at 6.1, 21.8, and 52.1 months, respectively, and all patients presented with locoregional failure.
  • In conclusion, Nasal-type NK/T cell lymphomas showed a poor response to the conventional anthracycline-based chemotherapy, and thus an investigation for an innovative therapy is urgently needed to improve survival in these patients.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anthracyclines / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Health Status. Humans. Killer Cells, Natural. Lymphoma, T-Cell. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2001 Mar;12(3):349-52 [11332147.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2179-88 [11304770.001]
  • [Cites] Int J Hematol. 2003 Oct;78(3):248-50 [14604284.001]
  • [Cites] Acta Oncol. 2003;42(7):779-83 [14690165.001]
  • [Cites] Histopathology. 2004 May;44(5):480-9 [15139996.001]
  • [Cites] Blood. 1992 May 1;79(9):2432-7 [1373974.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):798-804 [1377163.001]
  • [Cites] Blood. 1993 Aug 1;82(3):687-8 [8393351.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):284-96 [7532919.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):666-70 [7884427.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):103-11 [8540601.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1207-10 [8608206.001]
  • [Cites] Histopathology. 1996 Feb;28(2):111-20 [8834518.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4501-13 [9192774.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S46-55 [9894469.001]
  • [Cites] J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):268-72 [10025761.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1097-108 [15205205.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):54-63 [10623693.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • (PMID = 15798768.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2361983
  •  go-up   go-down


83. De Re V, Simula MP, Caggiari L, Ortz N, Spina M, Da Ponte A, De Appolonia L, Dolcetti R, Canzonieri V, Cannizzaro R: Protein expression profile of celiac disease patient with aberrant T cell by two-dimensional difference gel electrophoresis. Ann N Y Acad Sci; 2007 Aug;1109:429-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein expression profile of celiac disease patient with aberrant T cell by two-dimensional difference gel electrophoresis.
  • One complication of celiac disease (CD) is refractory CD.
  • These patients frequently show aberrant intraepithelial T cell clones and an increasing risk of evolution into enteropathy-associated T cell lymphoma (EATL).
  • There is debate in the literature whether these cases are actually a smoldering lymphoma from the outset.
  • The mechanism inducing T cell proliferation and prognosis remains unknown.
  • Only few single cases have been tested presently, nevertheless, in all of them a clinical improvement has been observed, while intraepithelial lymphocytes (IELs) effectively targeted by alemtuzumab are still a debated issue.
  • Using 2D-DIGE, we found hyperexpressed proteins specifically associated with aberrant T cell in a patient with CD by comparing the protein expression with that of patients with CD and polyclonal T cell or with that of control subjects (patients with polyclonal T cell and no CD).
  • Proteins with a higher expression in duodenal biopsy of the patient with aberrant T cell were identified as IgM, apolipoprotein C-III, and Charcot-Leyden crystal proteins.
  • These preliminary data allow hypothesizing different clinical effects of alemtuzumab in patients with CD, since besides the probable effect of alemtuzumab on T cell, it could effect inflammatory-associated CD52(+) IgM(+)B cell and eosinophils cells, known to produce IgM and Charcot-Leyden crystal proteins, which we demonstrated to be altered in this patient.
  • Results also emphasize the possible association of apolipoprotein with aberrant T cell proliferation.
  • [MeSH-major] Celiac Disease / metabolism. Electrophoresis, Gel, Two-Dimensional / methods. Proteomics / methods. T-Lymphocytes / metabolism
  • [MeSH-minor] Adult. Aged. Apolipoprotein C-III / metabolism. B-Lymphocytes / immunology. B-Lymphocytes / metabolism. Female. Glycoproteins / metabolism. Humans. Immunoglobulin M / immunology. Immunoglobulin M / metabolism. Lysophospholipase / metabolism. Male. Middle Aged. Receptors, Antigen, T-Cell, gamma-delta / genetics

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785332.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoprotein C-III; 0 / Glycoproteins; 0 / Immunoglobulin M; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / lysolecithin acylhydrolase; EC 3.1.1.5 / Lysophospholipase
  •  go-up   go-down


84. Oka K, Nagayama R, Mori N: Epstein-Barr virus-associated proliferative disorder presenting as Hodgkin's lymphoma and developing as aggressive natural killer-cell leukemia 19 years later: a case report of composite lymphoma. Pathol Res Pract; 2009;205(10):730-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated proliferative disorder presenting as Hodgkin's lymphoma and developing as aggressive natural killer-cell leukemia 19 years later: a case report of composite lymphoma.
  • We describe a patient who was diagnosed as having classic Hodgkin's lymphoma at 29 years of age, and aggressive natural killer-cell leukemia at 48 years.
  • Hodgkin and Reed-Sternberg cells in the lymph node expressed CD30, CD15, T-cell intracellular antigen-1 (TIA-1), perforin, granzyme B, and Epstein-Barr virus-encoded RNA (EBER).
  • Natural killer-cell leukemia cells in the bone marrow expressed cytoplasmic CD3epsilon, TIA-1, perforin, granzyme B, and EBER, and some neoplastic cells expressed CD56 (123C3).
  • Fluorescence-activated cell sorter (FACS) analysis showed that neoplastic cells expressed CD56.
  • Neither a rearrangement band of the T-cell receptor gene nor that of the immunoglobulin heavy chain gene was detected.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / pathology. Leukemia, Large Granular Lymphocytic / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Flow Cytometry. Herpesvirus 4, Human. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269751.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK: Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant; 2007 Jan;13(1):116-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
  • Relapsed acute leukemia after allogeneic transplantation has a poor prognosis and most reports have focused on the role of second transplantations in relapsed patients.
  • We report our single-institution experience on the management of relapsed acute leukemia after allogeneic transplantation.
  • We aimed to describe the outcome of relapsed acute leukemia after allogeneic transplantation at our institution and investigate whether maneuvers intended to augment donor T cell allogeneic reactivity were associated with durable graft-versus-leukemia effects.
  • We analyzed 310 patients with acute leukemia who received allogeneic hematopoietic progenitor cell transplants from HLA-matched donors between 1982 and 2005 (229 with acute myelogenous leukemia, 81 with acute lymphoblastic leukemia).
  • Factors associated with relapse incidence, therapy for relapse, response to treatment, and post-relapse survival were assessed.
  • One hundred of 310 patients (32%) with acute leukemia relapsed after transplantation, including 28 of 81 patients (35%) with acute lymphoblastic leukemia and 72 of 229 (31%) with acute myelogenous leukemia at a median of 136 days after transplantation.
  • A multivariable Cox regression analysis indicated that a longer time to relapse after transplantation, peripheral blood as source of stem cells, and initial post-relapse therapy with cytokines, donor lymphocyte infusions, or second transplants were associated with improved post-relapse survival (P <.001, <.001, and .025).
  • The outlook for patients with post-transplant relapse of acute leukemia is extremely poor; currently, no single therapy consistently results in durable remissions.
  • Our study highlights the need for clinical trials in this area.
  • [MeSH-major] Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cell Transplantation. Interferon-alpha / therapeutic use. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Immunotherapy / methods. Kaplan-Meier Estimate. Male. Middle Aged. Mortality. Prognosis. Retrospective Studies. Salvage Therapy / methods. Transplantation, Homologous / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222760.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


86. Kannangara AP, Levitan D, Fleischer AB Jr: Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. J Dermatolog Treat; 2009;20(3):169-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
  • BACKGROUND: Various combination therapies are used in refractory cutaneous T-cell lymphoma (CTCL).
  • RESULTS: Twelve patients with CTCL stage IA-IIB disease who received a combination of bexarotene and methotrexate were identified.
  • Tolerance to the treatment was good and commonly observed side effects were hyperlipidemia, elevated liver transaminases and a decreased white blood cell count.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, T-Cell, Cutaneous / drug therapy. Lymphoma, T-Cell, Cutaneous / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Administration, Oral. Adult. Age Factors. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Mycosis Fungoides / drug therapy. Mycosis Fungoides / mortality. Mycosis Fungoides / pathology. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sex Factors. Survival Rate. Tetrahydronaphthalenes / administration & dosage. Tetrahydronaphthalenes / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19016373.001).
  • [ISSN] 1471-1753
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


87. Tözsér J, Weber IT: The protease of human T-cell leukemia virus type-1 is a potential therapeutic target. Curr Pharm Des; 2007;13(12):1285-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The protease of human T-cell leukemia virus type-1 is a potential therapeutic target.
  • Human T-cell leukemia virus type-1 (HTLV-1) is associated with a number of human diseases.
  • Although the mechanism by which the virus causes diseases is still not known, studies indicate that viral replication is critical for the development of HTLV-1 associated myelopathy, and initial studies suggested that blocking replication with reverse transcriptase inhibitors had a therapeutic effect.
  • Therefore, based on the success of HIV-1 protease inhibitors, the HTLV-1 protease is also a potential target for chemotherapy.
  • Furthermore, mutated residues in HIV-1 protease that confer drug resistance are frequently seen in equivalent positions of other retroviral proteases, like HTLV-1 protease.
  • Therefore, comparison of HTLV-1 and HIV-1 proteases is expected to aid the rational design of broad spectrum inhibitors effective against various retroviral proteases, including the mutant HIV-1 enzymes appearing in drug resistance.
  • This review describes the characteristics of HTLV-1 protease, makes comparison with HIV-1 protease, and discusses the status of inhibitor development for the HTLV-1 protease.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504236.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM062920; United States / NIGMS NIH HHS / GM / GM 062920; United States / FIC NIH HHS / TW / TW01001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protease Inhibitors; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / HTLV-1 protease
  • [Number-of-references] 45
  •  go-up   go-down


88. Okayama A: [Natural history of human T-lymphotropic virus type 1 (HTLV-1) infection]. Rinsho Byori; 2005 Sep;53(9):837-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural history of human T-lymphotropic virus type 1 (HTLV-1) infection].
  • The natural history of human T-lymphotropic virus type-1 (HTLV-1) infection has been difficult to be clarified, because only a small proportion of HTLV-1 carriers develop adult T-cell leukemia(ATL) after a long incubation period.
  • We have performed a long-term follow-up study of HTLV-1 carriers for 17 years.
  • Based on the findings of this study and other studies, the natural history of HTLV-1 carriers is hypothesized as follows.
  • The major routes of infection of this virus are from mother to child, between spouses, and through blood products.
  • The target of HTLV-1 infection is CD4 positive peripheral blood mononuclear cells (PBMCs).
  • Clonal expansion of infected cells is likely to be contributing to the maintenance of the HTLV-1 infection.
  • Finally, some of these clones, which acquired the accumulation of genomic abnormality, develop the pre-leukemic state.
  • The increased number of certain T-cells due to HTLV-1 infection may also cause imbalance of the immune system, resulting in immune dysfunction or inflammatory diseases like myelopathy and uveitis.
  • Therefore, it seems to be important to find ways to prevent HTLV-1 associated diseases among the carriers especially those with many infected cells.
  • [MeSH-major] HTLV-I Infections / virology
  • [MeSH-minor] Adult. Carrier State. Female. Humans. Leukemia-Lymphoma, Adult T-Cell / virology. Male. Paraparesis, Tropical Spastic / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235837.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 26
  •  go-up   go-down


89. Yu Y, Yuan F, Li X, Lin D, Lan Z, Rao CV, Lei Z: Luteinizing hormone receptor deficiency increases the susceptibility to alkylating agent-induced lymphomagenesis in mice. Horm Cancer; 2010 Oct;1(5):256-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have revealed a close link between luteinizing hormone (LH)/human chorionic gonadotropin (hCG) signaling and oncogenesis in gonadal and nongonadal tissues.
  • To investigate whether genetic ablation of LH receptor (Lhr) affects the animal's oncogenic susceptibility, adult female wild-type (wt), heterozygous, and homozygous Lhr knockout (LhrKO) mice were intraperitoneally injected with an alkylating agent, N-methyl-N-nitrosourea (MNU, 50 mg/kg of body weight).
  • The results showed that MNU induced non-Hodgkin's thymic and lymphonodus lymphomas in 70.6% and 100% of heterozygous and homozygous animals, respectively, compared with 35.7% in wt siblings.
  • All tumors were immunostained-positive for a T-cell specific marker, CD3, but not for a B-cell marker, CD22, suggesting that all the lymphomas arose from T-cells, which are known to be LH/hCG receptor-positive.
  • There was no rearrangement of the Lhr gene locus or differences in thymic cell proliferation among the genotypes.
  • In conclusion, MNU induced a higher incidence and an earlier onset of aggressive lymphomas in LhrKO animals, which may be associated with a reduction in apoptosis of thymocytes.

  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Springer Science+Business Media, LLC 2010
  • [Cites] Nature. 1994 Jun 9;369(6480):455-61 [8202136.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):541-6 [12663516.001]
  • [Cites] Nature. 1995 May 4;375(6526):64-8 [7723844.001]
  • [Cites] Mol Cell Endocrinol. 1995 Apr 28;111(1):R13-7 [7544304.001]
  • [Cites] Growth Dev Aging. 1995 Fall;59(3):139-48 [8675368.001]
  • [Cites] Carcinogenesis. 1996 Apr;17(4):771-7 [8625490.001]
  • [Cites] Immunol Cell Biol. 1996 Apr;74(2):134-43 [8724000.001]
  • [Cites] Eur J Cancer Prev. 1996 Sep;5 Suppl 1:11-7 [8972287.001]
  • [Cites] Biol Reprod. 1997 Jan;56(1):67-72 [9002634.001]
  • [Cites] Leuk Res. 1997 Mar;21(3):189-98 [9111162.001]
  • [Cites] Arch Histol Cytol. 1997 Mar;60(1):29-38 [9161687.001]
  • [Cites] Exp Gerontol. 1997 Jul-Oct;32(4-5):415-29 [9315446.001]
  • [Cites] Oncogene. 1997 Oct 23;15(17):2127-32 [9366529.001]
  • [Cites] Neuroimmunomodulation. 1999 Jan-Apr;6(1-2):126-36 [9876243.001]
  • [Cites] Neuroimmunomodulation. 1999 Jan-Apr;6(1-2):137-42 [9876244.001]
  • [Cites] Mol Cell Endocrinol. 2005 Apr 29;234(1-2):117-26 [15836960.001]
  • [Cites] Biol Reprod. 2005 Nov;73(5):860-5 [16033998.001]
  • [Cites] Hum Reprod. 2006 Apr;21(4):936-42 [16361283.001]
  • [Cites] Cell Death Differ. 2006 Sep;13(9):1495-505 [16341126.001]
  • [Cites] Mol Cell Endocrinol. 2007 Apr 15;269(1-2):51-60 [17367919.001]
  • [Cites] Mol Cell Endocrinol. 2007 Apr 15;269(1-2):26-33 [17382461.001]
  • [Cites] Mol Cell Endocrinol. 2007 Apr 15;269(1-2):2-8 [17382462.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2700-7 [17119127.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2650-8 [17585052.001]
  • [Cites] Int Immunopharmacol. 2008 Jan;8(1):71-9 [18068102.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59 [18097445.001]
  • [Cites] Mol Hum Reprod. 2009 Nov;15(11):703-11 [19710244.001]
  • [Cites] Front Biosci. 2000 Mar 1;5:D343-52 [10704433.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13307-14 [10788437.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):158-68 [11063638.001]
  • [Cites] Mol Endocrinol. 2001 Jan;15(1):184-200 [11145749.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5258-63 [11536039.001]
  • [Cites] EMBO J. 2003 May 1;22(9):2255-63 [12727891.001]
  • [Cites] Biol Reprod. 2003 Jul;69(1):338-46 [12672665.001]
  • [Cites] Cancer Sci. 2003 Mar;94(3):240-3 [12824916.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4281-6 [12874038.001]
  • [Cites] Cancer Sci. 2003 Aug;94(8):668-71 [12901790.001]
  • [Cites] Endocrinology. 2003 Sep;144(9):4123-33 [12933687.001]
  • [Cites] Horm Metab Res. 2003 Aug;35(8):502-5 [12953169.001]
  • [Cites] J Biol Chem. 2004 Jun 11;279(24):25503-10 [15044447.001]
  • [Cites] CA Cancer J Clin. 2004 Sep-Oct;54(5):260-72 [15371284.001]
  • [Cites] Boll Soc Ital Biol Sper. 1986 Jun 30;62(6):763-70 [3024676.001]
  • [Cites] J Endocrinol. 1987 Mar;112(3):345-50 [2951474.001]
  • [Cites] J Reprod Immunol. 1988 Aug;13(3):263-75 [3139875.001]
  • [Cites] J Cell Biol. 1989 Jun;108(6):2423-34 [2472407.001]
  • [Cites] Acta Endocrinol (Copenh). 1989 Dec;121(6):833-40 [2532849.001]
  • [Cites] Jpn J Cancer Res. 1991 Dec;82(12):1397-405 [1778764.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):849-52 [8479523.001]
  • [Cites] Chem Res Toxicol. 1993 Nov-Dec;6(6):771-85 [8117915.001]
  • [Cites] Endocr Rev. 2002 Apr;23(2):141-74 [11943741.001]
  • [Cites] Peptides. 2002 May;23(5):1011-4 [12084534.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3114-21 [12130577.001]
  • [Cites] Carcinogenesis. 2002 Oct;23(10):1701-11 [12376480.001]
  • [Cites] J Exp Ther Oncol. 2002 May-Jun;2(3):133-45 [12415629.001]
  • [Cites] Breast Cancer Res Treat. 2003 Feb;77(3):253-64 [12602925.001]
  • [Cites] Biol Reprod. 2003 Mar;68(3):888-95 [12604639.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1322-6 [7877975.001]
  • (PMID = 21666843.001).
  • [ISSN] 1868-8500
  • [Journal-full-title] Hormones & cancer
  • [ISO-abbreviation] Horm Cancer
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD057501-01; United States / NICHD NIH HHS / HD / R01 HD057501; United States / NICHD NIH HHS / HD / R01 HD057501-01; United States / NICHD NIH HHS / HD / R01-HD057501
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Receptors, LH; 684-93-5 / Methylnitrosourea
  • [Other-IDs] NLM/ NIHMS280254; NLM/ PMC3110697
  • [Keywords] NOTNLM ; Apoptosis / Gene knockout / LH/hCG receptor / Lymphoma / MNU / Thymus
  •  go-up   go-down


90. Shimizu Y, Takamori A, Utsunomiya A, Kurimura M, Yamano Y, Hishizawa M, Hasegawa A, Kondo F, Kurihara K, Harashima N, Watanabe T, Okamura J, Masuda T, Kannagi M: Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages. Cancer Sci; 2009 Mar;100(3):481-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages.
  • Human T-cell leukemia virus type-1 (HTLV-1)-specific T-cell immunity, a potential antitumor surveillance system in vivo, is impaired in adult T-cell leukemia (ATL).
  • In this study, we aimed to clarify whether the T-cell insufficiency in ATL is present before the disease onset or occurs as a consequence of the disease.
  • We investigated T-cell responses against Tax protein in peripheral blood mononuclear cells (PBMCs) from individuals at earlier stages of HTLV-1-infection, including 21 asymptomatic HTLV-1 carriers (ACs) and four patients with smoldering-type ATL (sATL), whose peripheral lymphocyte count was in normal range.
  • The latter group was further divided to two subgroups with or without emergence of Tax-specific responses following depletion of CC chemokine receptor 4 (CCR4)(+) cells that contained HTLV-1-infected cells.
  • In the PBMCs with Tax-specific responses, CD8(+) cells efficiently suppressed HTLV-1 p19 production in culture.
  • The remaining group without the emergence of Tax-specific response after CCR4(+) cell-depletion included at least two sATL and one AC samples, which spontaneously produced HTLV-1 p19 in culture, where tetramer-binding, Tax-specific cytotoxic T-lymphocytes were either undetectable or unresponsive.
  • Our results indicated that HTLV-1-specific T-cell responsiveness widely differed among HTLV-1 carriers, and that impairment of HTLV-1-specific T-cell responses was observed not only in advanced ATL patients but also in a subpopulation at earlier stages, which was associated with insufficient control of HTLV-1.
  • [MeSH-major] Gene Products, tax / immunology. HTLV-I Infections / immunology. Leukemia-Lymphoma, Adult T-Cell / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Adult. Aged. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Human T-lymphotropic virus 1 / immunology. Humans. Immunologic Surveillance. Male. Middle Aged. Receptors, CCR4 / metabolism

  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19154412.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCR4 protein, human; 0 / Gene Products, tax; 0 / Receptors, CCR4
  •  go-up   go-down


91. Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH: CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol; 2009 Dec;33(12):1860-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The major differential diagnosis for a primary cutaneous T-cell lymphoproliferative disorder with CD30 (Ki-1) positivity includes primary cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, pagetoid reticulosis and transformed mycosis fungoides (MF).
  • The proportions of positive cells were determined and correlated with each other as well as with age, stage at diagnosis, maximum stage and survival.
  • All cases had at least rare dermal CD30-positive cells.
  • Higher percentages of dermal CD30 and Ki-67-positive cells were associated with a higher stage at diagnosis, and together with epidermal CD30, associated with a higher maximum stage.
  • The proportion of CD30 and Ki-67-positive cells did not correlate with each other.

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Apr 1;95(7):2212-8 [10733487.001]
  • [Cites] Cell Prolif. 1997 Jan;30(1):37-47 [9332493.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1150-9 [9694702.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):625-36 [9711925.001]
  • [Cites] Dermatology. 1998;197(2):123-6 [9732159.001]
  • [Cites] Histopathology. 1998 Sep;33(3):240-7 [9777390.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3376-80 [9787176.001]
  • [Cites] J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):914-24 [10365922.001]
  • [Cites] Haematologica. 2005 Feb;90(2):200-6 [15710572.001]
  • [Cites] J Am Acad Dermatol. 2005 Jul;53(1):158-63 [15965442.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):575-83 [16410787.001]
  • [Cites] Am J Clin Pathol. 2006 May;125(5):727-36 [16707374.001]
  • [Cites] J Am Acad Dermatol. 2006 Aug;55(2):276-84 [16844512.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):805-12 [17327602.001]
  • [Cites] Br J Dermatol. 2007 Aug;157(2):284-9 [17573879.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1713-22 [17540844.001]
  • [Cites] Prilozi. 2007 Jul;28(1):39-55 [17921917.001]
  • [Cites] J Am Acad Dermatol. 2007 Nov;57(5):782-90 [17646032.001]
  • [Cites] J Dermatol Sci. 2008 Feb;49(2):125-32 [17826963.001]
  • [Cites] G Ital Dermatol Venereol. 2008 Feb;143(1):15-9 [18833048.001]
  • [Cites] Br J Dermatol. 2008 Sep;159(4):881-6 [18644018.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3082-7 [18647960.001]
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2081-90 [19021050.001]
  • [Cites] J Am Acad Dermatol. 2009 Feb;60(2):231-5 [19026464.001]
  • [Cites] J Clin Pathol. 2009 Feb;62(2):128-38 [18794197.001]
  • [Cites] Mod Pathol. 2000 May;13(5):502-10 [10824921.001]
  • [Cites] Am J Dermatopathol. 2000 Jun;22(3):212-6 [10871063.001]
  • [Cites] Blood. 2001 Feb 1;97(3):624-30 [11157477.001]
  • [Cites] J Cutan Pathol. 2001 Aug;28(7):356-62 [11437941.001]
  • [Cites] Arch Dermatol. 2002 Feb;138(2):199-203 [11843640.001]
  • [Cites] Eur J Haematol. 2002 Jul;69(1):11-20 [12270057.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3369-73 [12384439.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):857-66 [12873880.001]
  • [Cites] Diagn Mol Pathol. 2003 Sep;12(3):142-50 [12960696.001]
  • [Cites] Cancer Treat Rep. 1979 Apr;63(4):725-8 [445521.001]
  • [Cites] Am J Pathol. 1988 Aug;132(2):265-77 [3261136.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):372-82 [3408055.001]
  • [Cites] Am J Pathol. 1990 Feb;136(2):261-6 [1968314.001]
  • [Cites] Hematol Oncol. 1990 Jul-Aug;8(4):215-27 [2210690.001]
  • [Cites] Am J Pathol. 1990 Dec;137(6):1447-51 [2260631.001]
  • [Cites] J Dermatol. 1991 Mar;18(3):152-60 [1885849.001]
  • [Cites] J Cutan Pathol. 1995 Feb;22(1):11-7 [7751472.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1423-30 [7503364.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1A):487-91 [9066700.001]
  • [Cites] J Am Acad Dermatol. 1997 Jul;37(1):58-67 [9216524.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):281-5 [9234572.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2429-36 [9310494.001]
  • [Cites] Am J Dermatopathol. 1998 Feb;20(1):1-6 [9504661.001]
  • (PMID = 19898220.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / RR000056-440857; United States / NCRR NIH HHS / RR / UL1 RR024153; United States / NCRR NIH HHS / RR / M01 RR000056-440857
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ NIHMS153861; NLM/ PMC3733448
  •  go-up   go-down


92. Willis SN, Stadelmann C, Rodig SJ, Caron T, Gattenloehner S, Mallozzi SS, Roughan JE, Almendinger SE, Blewett MM, Brück W, Hafler DA, O'Connor KC: Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain; 2009 Dec;132(Pt 12):3318-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
  • Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system (CNS) that is thought to be caused by a combination of genetic and environmental factors.
  • To date, considerable evidence has associated Epstein-Barr virus (EBV) infection with disease development.
  • To assess whether EBV infection is a characteristic feature of multiple sclerosis brain, a large cohort of multiple sclerosis specimens containing white matter lesions (nine adult and three paediatric cases) with a heterogeneous B cell infiltrate and a second cohort of multiple sclerosis specimens (12 cases) that included B cell infiltration within the meninges and parenchymal B cell aggregates, were examined for EBV infection using multiple methodologies including in situ hybridization, immunohistochemistry and two independent real-time polymerase chain reaction (PCR) methodologies that detect genomic EBV or the abundant EBV encoded RNA (EBER) 1, respectively.
  • We report that EBV could not be detected in any of the multiple sclerosis specimens containing white matter lesions by any of the methods employed, yet EBV was readily detectable in multiple Epstein-Barr virus-positive control tissues including several CNS lymphomas.
  • Our finding that CNS EBV infection was rare in multiple sclerosis brain indicates that EBV infection is unlikely to contribute directly to multiple sclerosis brain pathology in the vast majority of cases.

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Neurol. 1987 Dec;44(12):1237-41 [2823754.001]
  • [Cites] J Immunol. 1986 Jul 15;137(2):498-501 [3013992.001]
  • [Cites] Nature. 1990 Jul 12;346(6280):183-7 [1694970.001]
  • [Cites] J Gen Virol. 1990 Jul;71 ( Pt 7):1481-95 [2165133.001]
  • [Cites] J Virol. 1991 Jul;65(7):3958-63 [1645805.001]
  • [Cites] Neuroepidemiology. 1991;10(2):62-5 [2062419.001]
  • [Cites] Neurology. 1992 Sep;42(9):1798-804 [1381067.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):975-6 [7520057.001]
  • [Cites] Cell. 1995 Mar 10;80(5):695-705 [7534214.001]
  • [Cites] Leuk Lymphoma. 1995 Sep;19(1-2):1-12 [8574154.001]
  • [Cites] Int Immunol. 1997 May;9(5):739-43 [9184919.001]
  • [Cites] J Exp Med. 1998 May 4;187(9):1395-402 [9565632.001]
  • [Cites] Ann Neurol. 1999 Jul;46(1):6-14 [10401775.001]
  • [Cites] Lancet. 1964 Mar 28;1(7335):702-3 [14107961.001]
  • [Cites] Eur J Neurol. 2004 Dec;11(12):833-4 [15667414.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1352-60 [15841210.001]
  • [Cites] JAMA. 2005 May 25;293(20):2496-500 [15914750.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):499-503 [16502434.001]
  • [Cites] Brain. 2006 Jun;129(Pt 6):1493-506 [16569670.001]
  • [Cites] Arch Neurol. 2006 Jun;63(6):839-44 [16606758.001]
  • [Cites] Curr Opin Rheumatol. 2006 Sep;18(5):462-7 [16896283.001]
  • [Cites] Rev Med Virol. 2006 Sep-Oct;16(5):297-310 [16927411.001]
  • [Cites] Lancet Neurol. 2006 Oct;5(10):887-94 [16987736.001]
  • [Cites] Neurology. 2006 Dec 12;67(11):2063-5 [17159123.001]
  • [Cites] Ann Neurol. 2007 Apr;61(4):288-99 [17444504.001]
  • [Cites] J Neurol. 2007 Apr;254(4):425-30 [17385083.001]
  • [Cites] J Virol. 2007 Jul;81(13):6777-84 [17459939.001]
  • [Cites] J Exp Med. 2007 Nov 26;204(12):2899-912 [17984305.001]
  • [Cites] Semin Neurol. 2008 Feb;28(1):17-28 [18256984.001]
  • [Cites] Neurology. 2008 Mar 25;70(13 Pt 2):1113-8 [18272866.001]
  • [Cites] Autoimmunity. 2008 May;41(4):298-328 [18432410.001]
  • [Cites] Mult Scler. 2008 Jun;14(5):595-601 [18566025.001]
  • [Cites] Brain. 2008 Jul;131(Pt 7):1712-21 [18550621.001]
  • [Cites] J Exp Med. 2008 Aug 4;205(8):1763-73 [18663124.001]
  • [Cites] Curr Opin Neurol. 2009 Jun;22(3):201-6 [19359987.001]
  • [Cites] J Neurol Sci. 2009 Nov 15;286(1-2):62-4 [19361810.001]
  • [Cites] Neurology. 1989 Jun;39(6):825-9 [2725877.001]
  • [Cites] IARC Sci Publ. 1985;(60):475-6 [4065951.001]
  • [Cites] Virchows Arch. 1999 Aug;435(2):79-86 [10599304.001]
  • [Cites] J Neurol Sci. 2000 Feb 1;173(1):32-9 [10675577.001]
  • [Cites] Neurology. 2000 Jul 25;55(2):178-84 [10908887.001]
  • [Cites] Hum Pathol. 2001 Dec;32(12):1382-7 [11774173.001]
  • [Cites] Nat Rev Immunol. 2001 Oct;1(1):75-82 [11905817.001]
  • [Cites] Clin Exp Immunol. 2003 Apr;132(1):137-43 [12653848.001]
  • [Cites] Trends Immunol. 2003 Nov;24(11):584-8 [14596882.001]
  • [Cites] N Engl J Med. 2004 Mar 25;350(13):1328-37 [15044644.001]
  • [Cites] J Clin Invest. 2004 Mar;113(6):788-94 [15067307.001]
  • [Cites] JAMA. 2004 Apr 21;291(15):1875-9 [15100207.001]
  • [Cites] J Virol. 2004 May;78(10):5194-204 [15113901.001]
  • [Cites] Lancet. 1971 Jan 23;1(7691):167-8 [4102189.001]
  • [Cites] Acta Neurol Scand. 1971;47(3):315-30 [5096759.001]
  • [Cites] JAMA. 1972 Apr 17;220(3):393-4 [5067110.001]
  • [Cites] Arch Neurol. 1983 Jul;40(7):406-8 [6860175.001]
  • [Cites] Arthritis Rheum. 1983 Jun;26(6):712-20 [6190485.001]
  • [Cites] Ann Neurol. 1985 Apr;17(4):371-7 [2988410.001]
  • [CommentIn] Brain. 2010 Dec;133(Pt 12):e157 [20739348.001]
  • [CommentIn] Brain. 2010 May;133(Pt 5):e137 [19917644.001]
  • (PMID = 19638446.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / P01AI39671; United States / NINDS NIH HHS / NS / P01NS38037; United States / NINDS NIH HHS / NS / R01NS024247; United States / NIDDK NIH HHS / DK / U01DK6192601
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral
  • [Other-IDs] NLM/ PMC2792367
  •  go-up   go-down


93. Chaiworapongsa T, Romero R, Tarca AL, Kusanovic JP, Gotsch F, Mittal P, Kim SK, Vaisbuch E, Mazaki-Tovi S, Erez O, Dong Z, Kim CJ, Yeo L, Hassan SS: A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. Am J Obstet Gynecol; 2010 Jun;202(6):550.e1-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia.
  • OBJECTIVE: The aim of this study was to examine if maternal plasma concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-2 change prior to the diagnosis of preeclampsia.
  • Cross-sectional analysis suggested that the median plasma sVEGFR-2 concentration in women destined to develop preeclampsia was significantly lower than that in normal pregnant women from 28-31 weeks of gestation (P = .001) or 6-10 weeks prior to the diagnosis (P < .001).
  • [MeSH-major] Pre-Eclampsia / blood. Pre-Eclampsia / diagnosis. Vascular Endothelial Growth Factor Receptor-2 / blood
  • [MeSH-minor] Adolescent. Adult. Biomarkers / blood. Cross-Sectional Studies. Enzyme-Linked Immunosorbent Assay. Female. Gestational Age. Humans. Longitudinal Studies. Middle Aged. Patient Selection. Pregnancy. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Preeclampsia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):548-53 [12496487.001]
  • [Cites] J Matern Fetal Neonatal Med. 2008 Jan;21(1):41-52 [18175243.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2348-51 [12727995.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Hypertens Pregnancy. 2003;22(2):143-8 [12908998.001]
  • [Cites] Am J Obstet Gynecol. 2001 Jan;184(2):146-52 [11174494.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Feb;43(2):474-82 [11818393.001]
  • [Cites] Surgery. 2002 Nov;132(5):857-65 [12464871.001]
  • [Cites] Mediators Inflamm. 2003 Oct;12(5):293-8 [